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aa    amino acids 
AD    autosomal dominant 
Ala    alanine 
Amp    ampicillin 
APS    ammoniumpersulfate 
AR    autosomal recessive 
Arg    arginine 
Asn     asparagine 
Asp    aspartic acid 
ATP    adenosinetriphosphate 
BAC    bacterial artificial chromosome 
bp    base pair 
BSA    bovine serum albumin 
cDNA    complementary DNA 
Ci    Curie 
cM    centimorgan 
CNS    central nervous system 
Cys    cysteine 
°C    degree Celsius 
Da    dalton 
dATP    deoxyadenosintriphosphate 
dCTP    deoxycytidintriphosphate 
dGTP    deoxyguanosintriphosphate 
dTTP    deoxythymidintriphosphate 
ddATP   dideoxyadeosintriphosphate 
ddCTP    dideoxycytidintriphosphate 
ddGTP   dideoxythymidintriphosphate 
ddTTP    dideoxythymidintriphosphate 
dH2O    distilled water 
DMSO   dimethylsulfoxide 
DNA    deoxyribonucleic acids 
DTT    dithiothreitol 
E.coli    Escherichia coli 
EDTA    ethylenediaminetetraacetic acid 
EST    expressed sequence tag 
EtBr    ethidium bromide 
EtOH    ethanol 
g    gram 
Gln    glutamine 
Glu    glutamic acid 
Gly    glycine 
et al    et altera 
His    histidine 
hr    hour 
HSP    hereditary spastic paraplegia 
Ile    isoleucine 
IPTG    isopropyl-β-D-thiogalactoside 
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kb    kilobase 
kDa    kilodalton 
KOAc    potassium acetate  
l    liter 
lac Z    the symbol of β-galactosidase gene 
LB    Luria-Bertani 
Leu    leucine 
LMP    low melting point 
Lys    lysine 
M    molar 
Mb    megabase 
Met    methionine 
min    minute 
ml    milliliter 
mM    millimolar 
µ    micro 
nm    nanometer 
NaOAc   sodium acetate  
ng    nanogram 
OD    optical density 
ORF    open reading frame 
ori    origin of replication 
p    pico 
PAC    P1-derived artificial chromosome 
PAGE    polyacrylamide gel electrophoresis 
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
pH    pH value 
PIC    polymorphism information content 
Phe    phenylalanine 
PMSF    phenylmethylsulfonylfluoride 
Pro    proline 
%(v/v)    percent of volume 
%(w/v)   percent of weight 
RNA    ribonucleic acids 
RNase    ribonuclease 
rpm    rotations per minute 
RT-PCR   reverse transcriptase PCR  
sec    second 
SDS    sodium dodecylsulfate 
Ser    serine 
SPG    spastic paraplegia 
STR    short tandem repeat 
STS    sequence tagged site 
TAE    Tris-Acetate-EDTA 
TBE    Tris-Borate-EDTA 
TE    Tris-EDTA 
TEMED   N,N,N’,N’,-tetramethylenediamine 
Thr    threonine 
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Tris    tris(hydroxymethyl)aminomethane 
Trp    tryptophan 
Tyr    tyrosine 
U    units 
µl    microliter 
UV    ultraviolet 
V    voltage 
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vs.    versus 
W    watt 
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1 Introduction 
Hereditary spastic paraplegias (HSP) (Mckusick number 1 182600) are a group of clinically 
and genetically diverse disorders characterized by progressive, generally severe, spasticity of 
lower extremity and in some cases upper extremities as well. Two groups of HSPs can be 
distinguished clinically by whether progressive spasticity occurs in isolation (pure HSP) or in 
combination with other neurologic abnormalities (complicated HSP), including optic 
neuropathy, retinopathy, extrapyramidal disturbance, dementia, ichthyosis, mental retardation, 
and deafness.2,3 However, there are few cases presenting intermediate clinical features. Pure 
HSP is more common and also genetically heterogeneous. On the other hand, Complicated 
HSP consists of many rare conditions which tend to be inherited as an autosomal recessive 
trait.4 Both forms can  be inherited in an autosomal dominant, autosomal recessive or X-
linked recessive pattern. Prevalence of HSP was estimated at  9 x 10-6 in Denmark,5 140 x 10-6 
in western Norway6 and 96 x 10-6 in northern Spain.7 
 
1.1 Pure Hereditary Spastic Paraplegia (Pure HSP) 
Pure HSP is the most common form of HSP. Approximately 70-80% of pure HSPs follow an 
autosomal dominant inheritance pattern (AD-HSP)8; autosomal recessive inheritance (AR-
HSP)9 is found in 20-30% of  cases and in very rare cases X-linked recessive inheritance (X-
HSP)10 occurs.  
 
1.1.1 Clinical Features of Pure HSP 
The first cases of pure HSP were described in 1880 by Strümpell11 who reported two brothers 
with an onset in middle life of progressive weakness and spasticity in the lower limbs. The 
clinical feature of pure HSP is the presence of a progressive spastic paraplegia mainly of the 
lower extremities. The disease severity ranges from completely asymptomatic (10-20%) to 
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wheelchairbound (10-15%). Patients develop leg stiffness and gait disturbance (stumbling and 
tripping) due to difficulty  in dorsiflexing the foot and weakness of hip flexion. Although 
weakness and hypertonicity are usually restricted to the lower limbs, upper limb hyperreflexia 
is  also common. Patients show weakness in addition to spasticity. The presence of urinary 
symptoms  is  likely.  About 50% of patients are affected by urinary frequency, urgency or 
incontinence. Diminished  sense of vibration is present in 20-65% of patients and 30-50% of 
patients have a Pes cavus. In addition, erectile impotence, mild upper limb incoordination, and 
absent ankle jerks were found in a small proportion of patients.2,4,8,12 The symptoms and signs 
of pure HSP are shown in Table 1. 
 
Harding9 subclassified autosomal dominant pure HSP in Type I and Type II. Type I has an 
early onset (before age 35) and slow progression of symptoms. Patients show greater 
spasticity than weakness. On the other hand, Type II has a later onset (after age 35) and 
demonstrates faster progression.  Dürr  et al.12 studied 23 families with pure autosomal 
dominant spastic paraplegia and found that the mean age of onset was 29, with a range 
between 1 and 68. Patients showed hyperreflexia in the upper limbs, sphincter disturbances, a 
decreased sense of vibration, and increased frequency of lower limb muscle weakness with 
disease duration. However, the clinical manifestations of early-onset (< age 29) and late-onset 
(> age 29) patients were not significantly different. Age at onset varied  both between and 
within families. Anticipation and imprinting did not occur. These results suggested that only 
genetic analyses could provide accurate classification of the pure HSP.   Fink et al.2 observed 
that the ages of onset overlap in autosomal dominant HSP kindred and also concluded that 
there did not appear to be a genetic basis for HSP classification based entirely on age of 
symptom onset. 
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Table 1. Symptoms and signs in pure HSP2,4,8,12 
A progressive spastic paraplegia 
Weakness and hypertonicity of legs 
Upper limb and jaw jerk hyperreflexia 
Urinary symptoms (urinary frequency, urgency, or hesitancy) 
Sphincter disturbances 
Decreased vibration sense 
Decreased joint position sense 
Absence of ankle jerks 
Babinski signs 
Hoffman’s signs 
Trömner’signs 
Pes cavus 
Clonus at ankles and knees 
Extensor plantar responses 
Mild upper limb incoordination 
Scoliosis (rare) 
 
 
1.1.2 Pathology 
The major neuropathologic feature of pure HSP is an axonal degeneration in the terminal 
portions of the longest corticospinal fibers and dorsal columns.8,13 Loss of anterior horn cells 
is observed in some cases.4 Neuronal cell bodies of degenerating fibers are normally 
preserved. There is no evidence of primary demyelination reported. The dorsal root ganglia, 
posterior roots, and peripheral nerves are normal13. 
 
1.2 Complicated Hereditary Spastic Paraplegia (Complicated HSP) 
In complicated HSP, spastic paraplegia appears with other disorders which include 
amyotrophy, cerebellar signs, optic atrophy, choreoathetosis/dystonia, sensory neuropahty, 
disordered skin pigmentation, macular degeneration/mental retardation (Kjelllin syndrome), 
Sjögren-Larsson syndrome, Mast syndrome, MASA syndrome (mental retardation, aphasia, 
shuffling gait, and adducted thumbs). Although these disorders are rare, spastic paraplegia is 
the common feature of them. The most common type of complicated HSP is spastic 
paraplegia associated with amyotrophy. This type frequently results in peroneal muscular 
atrophy syndrome or hereditary motor and sensory neuropathy. In addition, brisk knee jerks 
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and extensor plantar responses are specific signs. Distal sensory loss is observed in 50% of 
patients. The age of onset ranges from early childhood to 50´s and some affected individuals 
show asymptomatic3,4. 
 
1.3 Molecular Genetics of HSP 
Distinguishing between pure and complicated HSP is still a useful criteria. However, 
molecular genetics allow the definitive distinction of HSP due to the expanding variety of 
phenotypes. Now at least 15 HSP loci can be differentiated by genetic analysis, and the gene 
defect has been identified beyond doubt in 4 loci. These findings are a first step towards an 
understanding o f the pathological mechanism of HSP at the molecular level.  
 
1.3.1 X-linked HSP 
Three X-linked HSP loci have been mapped to Xq28 (SPG1;312900), Xq22 
(SPG2;312920),.Xq11.2 (SPG16;300266). 
 
SPG1 
Kenwrick  et al.14 reported a complicated X-HSP and mapped the disease locus to DXS15 and 
DXS52 on  the long arm of the X chromosome (Xq28).  All patients examined had mental 
retardation. Winter  et al.15 presented evidence  showing that the family described by 
Kenwrick  et al. was an instance of MASA syndrome. Later, Schrander-Stumpel et al.16 
proposed that MASA syndrome and X-linked hydrocephalus are allelic. Jouet et al.17 reported 
that the mutations  in L1CAM gene resulted in X-HSP, MASA syndrome, and X-linked 
hydrocephalus and thus all three syndromes are allelic disorders. L1CAM is a cell surface 
glycoprotein which is expressed in the axon of postmitotic neurons and is involved in 
neuronal migration and neurite extension.  
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SPG2 
Pure X-HSP is rare. The first genetic linkage of a pure form of spastic paraplegia was 
presented by Keppen et al.10 The mutation is linked to markers DXS17 and YNH3 located in 
the Xq21-q22 region. Bonneau et al.18 proposed that this pure X-HSP mapped to Xq21. 
However, this form could not be separated from the complicated variant because some 
members had mental retardation. This pure X-HSP was designated SPG2. Saugier-Veber et 
al.19 demonstrated that the gene for proteolipid protein was the closest marker mapped to 
Xq21  reported by Bonneau et al. They also found a His139Tyr mutation in exon 3B of the 
PLP gene in an affected male. PLP encodes two myelin proteins, PLP and DM20, and is 
involved in oligodendrocyte maturation and myelin sheath compaction. The His139Tyr 
mutation observed in this family  results in production of  a mutant PLP but wild-type DM20. 
Kobayshi et al20 reported the linkage results of the family with X-linked HSP whose 
symptoms began as pure spastic paraplegia, but later developed nystagmus, dysarthria, sensory 
disturbance or mental retardation. The half of patients had optic atrophy. Muscle wasting and 
joint contractures were observed in later symptoms. The patients needed crutches or 
wheelchair in their early adulthood The disease locus was mapped to the region Xq21.3-q24 
which includes the PLP gene. 
 
SPG16 
Another complicated X-HSP was reported by Steinmüller et al. 22 The patients were 
quadriplegic and had motor aphasia, reduced vision, mild mental retardation, and dysfunction 
of the bowel and bladder. Onset of the symptoms occurred during the first 3 months of life. 
Nystagmus and dorsal flexion of the great toes were observed in the beginning development 
of the symptoms. Spasticity occurred first in the lower and then upper extremities, and motor 
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development was delayed. The patients never learned to walk and all females of the family 
were normal. The authors assigned the disease locus to Xq11.2-q23 by linkage and haplotype 
analysis. They performed mutation analysis of  the PLP gene which was mapped to this region 
but no mutation was detected.  
 
1.3.2 Autosomal Recessive HSP 
Loci for autosomal recessive forms of SPG have been mapped to chromosomes 8p 
(SPG5A;270800), 16q (SPG7; 602783), 15q (SPG11; 604360), and 3q (SPG14; 605229).  
 
SPG5A 
Hentati et al.23 first reported a pure AR-HSP locus and the patients examined showed a mild 
loss of vibratory and positiona sense of the toes and dysfunction of the bladder sphincter. The 
age of onset ranged from one to 20 years. This locus was mapped to a 32.2 cM (centimorgen) 
interval in the pericentromeric region of chromosome 8 between 8p12 and 8q13. 
 
SPG7 
De Michele et al.24 described a large consanguineous family with complicated AR-HSP. All 
cases had abnormal gait and vibration sense was frequently decreased in legs. Hypernasal, 
slowed speech, dysphagia, urinary urgency, scoliosis, pes cavus and pale optic disk appeared 
in some cases. There were no cerebellar or extrapyramidal signs in any of 6 affected 
individuals. The mean age of onset was 30±8 years in this family. This locus was linked to 
markers D16S413 and D16S303 on 16q24.3. Soon after the mapping, the same team25 
identified a gene within this region that encodes a novel protein, paraplegin that is highly 
homologous to yeast mitochondrial ATPases, AFG3, RCA1, and YME1, which have both 
proteolytic and chaperone-like activities at the inner mitochondrial membrane. 
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Immunofluorescence analysis  and import experiments showed that paraplegin localizes to 
mitochondria. Analysis of muscle biopsies showed  typical signs of OXPHOS defects that 
include cytochrome c oxidase deficient  fibers and the presence of  subsarcolemmal 
accumulation of mitochondria of bizarre shape. These data indicated that a  mitochondria 
protein defect in HSP. Paraplegin is composed of 17 exons and spans approximately 52 kb. 
The cDNA length of this gene is approximately 3.2kb and it encodes a 795 amino acid 
protein. A 9.5kb deletion and two frameshift mutations which were found in one pure and in 
one complicated HSP family have been reported. 
 
Paraplegin and yeast mitochondrial ATPases (AFG3, RCA1, and YME1) are the members of 
AAA protein family ( ATPase associated with a variety of cellular activities). AAA proteins 
play essential roles in peroxisome biogenesis, the assembly of mitochondrial membrane 
proteins, cell cycle control, mitotic spindle formation, cytoskeletal interactions, vesicle 
secretion, signal transduction, and transcription. These proteins are characterized by a highly 
conserved AAA motif. This motif forms a 230-250 amino acids domain that includes the 
Walker homology sequences of P-loop ATPases and other regions of similarity unique to 
AAA family such as Walker B and the minimal AAA consensus sequence. The motif confers 
ATPase activity. Evolutionary conservation of the AAA domain ranges from eubacteria and 
archaebacteria to modern eukaryotes and tends to be homologous in regions outside  the AAA 
domain. All members of the AAA family are Mg2+-dependent ATPases and include 
metalloproteases, proteins involved in vesicle and organelle biogenesis, cell-cycle regulators , 
components of the 26S proteasome, and  chaperone and chaperone-like protein families 
(AAA+ class).26,27,28  
SPG11 
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The third AR-HSP locus (SPG11) was described by Martínez Murillo et al.29 The patients in 
eight examined AR-HSP families had the common features of spasticity and weakness in the 
lower limbs, hyperreflexia, extensor plantar reflexes. Mental retardation was present in two 
families. The age of onset ranged from one to 50 years. In seven of eight AR-HSP families, 
the disease locus was mapped to chromosome 15q13-q15, a 6.41 cM region between markers 
D15S971 and D15S118. The other family showed significant linkage to the previously 
characterized 8q locus.  
 
SPG14 
Recently, Vazza et al.30 described a consanguineous Italian family with HSP. The clinical 
features were spastic gait, hyperreflexia, mild lower limb hypertonicity. Bilateral pes cavus , 
extensor plantar responses, and mild mental retardation were present in all cases. The average 
age of onset was 30. All three patients were able to walk without aid. The authors performed a 
whole genome scan in another AR-HSP family and reported a new AR-HSP locus. The 
disease locus assigned to 3q27-q28. 
 
1.3.3 Autosomal Dominant HSP 
To date, 8 AD-HSP loci have been mapped to chromosome 14q (SPG3;182600), 2p 
(SPG4;182601), 15q (SPG6;600363), 8q (SPG8;603563), 10q (SPG9;601162), 12p 
(SPG10;604187), 19q (SPG12;604805), 2q (SPG13;605280).  
 
SPG3 
The first AD-HSP locus was reported by Hazan et al.31 In one of three AD-HSP families the 
disease was linked to locus AFM267zd5 on chromosome 14q. The clinical feature was very 
similar in three families. Spastic gait was the prominent sign in all patients, with a variable 
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degree of severity. Some affected individuals (18.75%) showed asymptomatic. The age of 
onset ranged from 2 to 50 years. Another two studies demonstrated that anticipation and early 
age of onset in two SPG3 linked families.32,33 
 
SPG4 
Hazan et al.34  reported the second AD-HSP locus in one Dutch and five French families. The 
average age of onset ranged from 20 to 39 years in these families. Wide variations of age of 
onset were observed within families. The symptoms occurs relatively nonprogressive. The 
authors mapped this disease locus to a 4 cM region flanked by loci D2S400 and D2S367. Fink 
et al.2 reviewed seven publications which included 67 pure AD-HSP families. Of the families, 
34 were indeterminate and the disease loci of 33 kindreds were mapped to chromosomes 2p, 
14q, and 15q. Of these 33 kindreds, the disease loci of 15 kindreds (45%) were linked to 
chromosome 2p, two (6%) were associated with chromosome 14q, and only one (3%) was 
associated with chromosome 15q. Scott et al.35 studied 11 Caucasian pedigrees with pure AD-
HSP to determine the linkage to the previously identified loci on 2p, 14q, and 15q. 
Chromosome 15q was excluded in  all families. There was evidence of linkage to 2p in five 
families and linkage to 14q in one family. The other five families remained indeterminate. In 
pure AD-HSP families, a high proportion have linkage to SPG4. 
 
In 1999, Hazan et al.36,37 identified the SPG4 gene (SPAST) by using positional cloning. 
SPAST  is composed of 17 exons spanning a region of approximately 90 kb. The cDNA of 
SPAST is 3263 bp containing a 1848 bp ORF preceded by a 125 bp 5’ UTR and followed by a 
1290 bp 3’ UTR. The promoter is predicted to be located at 43 bp upstream  from the first 
base of SPAST exon 1. The ORF encodes a 616 amino acid protein which is named spastin. 
The spastin carboxy terminus has striking homology with several members of AAA family 
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and contains three conserved ATPase domains, including Walker motifs A and B and the 
AAA minimal consensus, found  at amino acid positions 382-389, 437-442 and 480-498 of 
spastin, respectively. Walker motif A ‘GPPFNFKT` corresponds to the ATP-binding domain. 
Two leucine-zipper domains are detected at amino acid positions 50-78 and 508-529 and a 
helix-loop-helix dimerization domain is located between amino acid positions 478 and 486. 
RT-PCR analysis reveals  that human SPAST and its mouse homologue are expressed early 
and ubiquitously in fetal and adult tissues. 
 
SPG6 
Fink et al.38 demonstrated the third AD-HSP locus in a large kindred extensively affected with 
pure AD-HSP. Neurologic examination of patients showed hyperreflexia, spasticity in the 
lower limbs, weakness of hip flexion and  ankle dorsiflexion, extensor plantar responses, 
diminished vibratory sense in the feet, and pes cavus. Bladder disturbance was present in 
some cases. The patients developed progressive gait disturbance at age 12 to 35 years and the 
average age of onset was 22±5.3 years. The authors mapped this disease locus to chromosome 
15q11.1.  
 
SPG8 
Hedera et al.39 examined a Caucasian kindred which developed insidiously progressive gait 
disturbance at age 22 to 60 years. Neurological examination demonstrated spastic diplegic gait 
disturbance, frank corticospinal -tract deficits in legs, weakness of hip flexion and ankle 
dorsiflexion, diminished vibratory sensation in the feet, and often, pes cavus. The patients in 
wheelchairs had mild muscle atrophy and bladder disturbance was present in some cases. The 
disease locus mapped to chromosome 8q23-q24, a 6.2 cM region between D8S1804 and 
D8S1774.  
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SPG9 
Seri et al.40 studied a large pedigree with complicated AD-HSP. The patients presented with 
bilateral cataracts, gastroesophageal reflux with persistent vomiting, and spastic paraparesis 
with amyotrophy. Severity of spastic paraparesis varied. Pes cavus and the Babinski signs, 
along with different degrees of muscle wasting localized  in the hands and “forelegs” (sic.) 
were present in some cases. The authors performed a genome wide scan and assigned this 
disease locus to a 12-cM region in 10q23.3-q24.2.  
 
SPG10 
Reid et al.41 reported a large family with pure AD-HSP. All but one affected members had a 
spastic gait abnormality, in addition to lower-limb reflexia. The asymptomatic affected 
individual was a carrier who had bilateral lower-limb hyperrefleixa, bilateral extensor-plantar 
responses, and unilateral sustained ankle clonus. The development of asymptomic to 
symptomatic history was observed in one patient.  The age of onset ranged from 8 to 40 years 
and the average age of onset was 10.8±9.6 years. The authors performed a genome wide scan 
data and mapped this pure ADHSP locus to chromosome 12q13, a 9.2 cM interval between 
markers D12S368 and D12S8334. Later, this interval was narrowed to a 6.95 cM region 
flanked by D12S270 proximally  and D12S355 distally by further genetic analysis.  
 
SPG12 
Recently, Reid et al.42 performed  a genome wide linkage screen of  a large Welsh family with 
AD-HSP which had previously reported43 but no linkage with known pure AD-HSP loci. The 
authors assigned this novel AD-HSP locus to 19q13, a 16.1 cM interval between markers 
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D19S868 and D19S902. The candidate region was narrowed to a 5 cM region between 
markers D19S868 and D19S220 by additional linkage analysis. 
 
SPG13 
Fontaine et al.44 excluded  all known AD-HSP loci  in a large family of French descent with 
pure AD-HSP. A genomewide scan demonstrated location of the disease locus in the 5 cM 
region flanked by D2S294 and D2S2195 on  2q24-q34. The authors compared the SPG13 
family with 12 SPG4 families. They found SPG13 family had significantly more patients 
without Babinski signs, with increased reflexes in arms and more severe handicaps than the 
patients of those 12 SPG4 families they examined. The severe handicaps score was obtained 
by dividing the disability score by disease duration (in years) and multiplying by 100. The 
authors defined a three point scale: 1 = normal gait or very light stiffness of the legs, 2 = 
inability to run, and 3 = either inability to walk without help or confinement to a wheelchair. 
The currently known HSP loci are summarized in Table 2. 
 
1.4 The purpose of this dissertation 
This dissertation began with study of a pure AD-HSP German family of three generations (see 
Figure 1). The family consists of 66 living members and 5 were diagnosed as symptomatic. 
The purpose of this dissertation is to determine the disease locus of this family and identify 
the mutation of this locus. The AD-HSP family was first tested for linkage with the 3 known 
AD-HSP loci at 2p, 14q, and 15q. The linkage results revealed that  the disease locus of this 
family was linked to chromosome 2p (SPG4). Therefore, this dissertation focuses on SPG4 
which is also the most common form of pure AD-HSP. Since there was no AD-HSP gene 
identified during the proceeding of this study, a physical map including YACs, BACs, and 
PACs was established to facilitate the isolation of gene. In addition, the proposed CAG 
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trinucleotide repeat expansion was investigated in this dissertation. Finally, using the 
sequence data of the recently cloned SPAST gene, the SPG4 family and members from nine 
pure HSP families were screened by direct sequencing. 
 
 
Table 2. Classification of hereditary spastic paraplegias 
____________________________________________________________________________________ 
HSP loci Gene  Gene  inheritance HSP forms References 
 location product mode   
____________________________________________________________________________________ 
SPG1 Xq28 L1CAM X-linked complicated Saugier-Veber14 et al. 
(1994) 
SPG2 Xq21 PLP X-linked complicated or pure 
(rare) 
Jouet17 et al.(1994) 
SPG3 14q11.2-q24.3 unknown AD pure Hazan31 et al. (1993) 
SPG4 2p21-p24 Spastin AD pure or complicated Hazan34 et al (1994) 
SPG5A 8p12-q13 unknown AR pure Hentati23 et al.(1994) 
SPG6 15q11.1 unknown AD pure Fink38 et al.(1995) 
SPG7 16q24.3 Paraplegin AR complicated or pure Casari24 et al.(1998) 
SPG8 8q23-q24 unknown AD pure Hedera39 et al.(1999) 
SPG9 10q23.1-q24.1 unknown AD complicated Seri 40et al.(1999) 
SPG10 12q13 unknown AD pure Reid41 et al.(1999) 
SPG11 15q13-q15 unknown AR complicated or pure Martinez29 et al.(1999) 
SPG12 19q13 unknown AD pure Reid42 et al.(2000) 
SPG13 2q24-q34 unknown AD pure Fontaine44 et al.(2000) 
SPG14 3q27-q28 unknown AR complicated Vazza30 et al.(2000) 
SPG16 Xq11.2 unknown X-linked complicated Steinmüller22et al.(1997)
____________________________________________________________________________________ 
AD: autosomal dominant inheritance    
AR: autosomal recessive inheritance    
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2 Materials 
 
2.1 Chemicals 
 
Acetic acid       Merck  (Darmstadt) 
Acrylease        Stratagene(La Jolla, USA) 
Agar Agar        Serva( Heidelberg) 
Agarose (LMP, ultrapure)      Gibco BRL (Gaithersburg, USA) 
Agarose NA       Pharmacia (Uppsala, Schweden) 
Agarose-Pulse Field      Amersham (Braunschweig) 
Ammoniumacetate      Sigma  (München) 
Ammoniumpersulfate(APS)    Serva (Heidelberg) 
Ampicilline        Bayer  (Leverkusen) 
Bacto Peptone       Difco (Detroit, USA) 
Bacto Yeast Extract       Difco (Detroit,USA) 
Boric acid            Merck (  Darmstadt) 
Bovine Serum Albumin(BSA)   Sigma  (München) 
5-Brom-4-chloro-3-indolyl-β-    Roth ( Karlsruhe) 
D-Galactopyranoside (X-gal)      
Bromphenolblue       Merck (Darmstadt) 
Calciumchloride       Merck (Darmstadt) 
Chloramphenicol     Boehringer (Mannheim) 
Chloroform        Merck (Darmstadt) 
Dextransulfate                                                           Sigma (München) 
D(+)-Glucose       Sigma (München) 
Dimethylformamide      Merck (Darmstadt) 
1,4-Dithiothret (DTT  )                                              Merck (Darmstadt) 
D(+)-Saccharose      Roth (Karlsruhe) 
Ethanol      Merck (Darmstadt) 
Ethidiumbromide (EtBr)     Serva (Heidelberg) 
Ethylendiaminteraacetate (EDTA-2Na)  Merck (Darmstadt) 
Ficoll type 400      Amersham (Braunschweig) 
Formaldehyde (37%)                                                 Merck (Darmstadt) 
Formamide        Merck (Darmstadt) 
Glutamine                                                                  Merck (Darmstadt) 
Glycerin (87%)                                                           Merck (Darmstadt) 
Glycogen        Boehringer  (Mannheim) 
Hydrogenchloride (HCl)                                             Merck (Darmstadt) 
HEPES                                                                       Sigma (München) 
Isopropanol        Merck (Darmstadt) 
Isopropyl-β-D-Thio-Galactopyranoside (IPTG)        Roth (Karlsruhe) 
Kanamycin                                                                Merck (Darmstadt) 
Polyvinylpyrrolidone      Sigma (München) 
Potassiumchloride(KCl)                                            Merck (Darmstadt) 
Potassiumacetate      Sigma  ( München) 
L-Arginin-HCl                                                           Roth (Karlsruhe) 
L-Histidine                                                                 Roth (Karlsruhe) 
L-Isoleucine                                                               Roth (Karlsruhe) 
L-Leucine                                                                   Roth (Karlsruhe) 
L-Methionine                                                             Roth (Karlsruhe) 
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L-Phenylalanine     Roth (Karlsruhe)  
L-Threonine      Roth (Karlsruhe) 
L-Tryptophan                                                            Roth (Karlsruhe) 
L-Tyrosine        Roth (Karlsruhe) 
L-Valine      Roth (Karlsruhe) 
Lysine                                                                        Merck (Darmstadt) 
Long Ranger gel solution    Amersham (Braunschweig) 
MDE gel solution                                                      FMC (Maine, USA) 
Magnesiumchloride      Merck  ( Darmstadt) 
Manganchloride                                              Merck (Darmstadt) 
3-[N-Morpholino]  propansulfonate   Sigma (München) 
(MOPS) 
Mineral oil       Sigma (München) 
N,N,N´,N´-Tetramethylethylendiamin  Serva (Heidelberg) 
(TEMED) 
Sodiumchloride      Merck (Darmstadt) 
Sodiumdodecylsulfate (SDS)    Serva (Heidelberg) 
Sodiumhydroxide (NaOH)    Merck (Darmstadt) 
Sodiumpyrophosphate     Sigma (München) 
Phenol       Merck (Darmstadt) 
Rotiphorese Gel 40                                                   Roth (Karlsruhe) 
Rubidiumchloride      Sigma (München) 
Sigmacote       Sigma (München) 
Spermidin       Sigma (München) 
Tris,[Tris(hydroxymethyl)-aminoethan]   USB (Braunschweig) 
Tri-sodiumcitrate      Merck (Darmstadt) 
Triton X-100                                                             Merck (Darmstadt) 
Urea        Merck (Darmstadt) 
Whatman 3 MM-Paper      Schleicher u. Schuell (Dassel) 
Xylene cyanol      Merck ( Darmstadt) 
 
2.2 Media 
 
I dYT medium : For 1 l medium   16 g Tryptone  
                                                                        10 g Yeast Extract  
                                                                        10 g NaCl 
 
II  LB medium : For 1 l medium  10 g Tryptone  
                                                                        5 g Yeast Extract  
                                                                       10 g NaCl 
 
III LB plate :    For 1 l preparation               1 l LB medium  
                                                                         15 g Agar-Agar 
 
IV NZYC-Broth:  For 1 l :                 5 g NaCl  
                                                            2 g MgCl2.6H2O   
                                                          10 g NZ amino acids (casein hydrolysate N-Z Amine A) 
                                                            5 g Bacto yeast extract 
                                                            1 g Bacto  casamino   acids (adjust pH to 7.4 ) 
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V 10 x (-) Ura, (-) Trp stock solution : For 1 l:      600 ml  0.5 mg/ml L-Tyrosin  
                                                                                 30 ml   7.5 mg/ml Adenine  
                                                                                 30 ml   7.5 mg/ml L-Arginine  
                                                                                 30 ml   7.5 mg/ml L-Histidine   
                                                                                 30 ml   7.5 mg/ml L- Methionine  
                                                                                 40 ml   7.5 mg/ml L-Lysine  
                                                                                 70 ml   7.5 mg/ml L-Phenylalanine 
                                                                                 80 ml   7.5 mg/ml L-Leucine 
                                                                                 80 ml   7.5 mg/ml L-Valine  
                                                                                 40 ml 7.5 mg/mlL-Isoleucine  
Each amino acid solution is separately prepared , autoclaved and stored at 4°C. 
 
VI Yeast nitrogen base stock solution  :  6.7 %(w/v) Yeast Nitrogen base solution 
      The stock solution is sterilized with filter and stored at room temperature. 
 
VII  (-) Ura, (-) Trp yeast medium:      
           For 100 ml                                         2 g Glucose  
                                                                   10 ml 10 x (-) Ura, (-) Trp stock solution  
                                                                   10 ml 6.7 % yeast  nitrogen base stock solution 
 
VIII   (-) Ura ,(-) Trp yeast agar plates  
           For 100 ml                                           2 g Agar-Agar 
                                                                    100 ml (-)Ura,(-)Trp Yeast medium 
 
2.3 Solutions and buffers 
 
I  Antibiotic solutions 
 
Ampicillin stock solution  :   50 mg/ml in dd H2O (store at -20°C) 
 
Kanamycin stock solution:   10 mg/ml in dd H2O (store at -20°C) 
 
Chloramphenicol stock solution:   34 mg/ml in ethanol (store at -20°C) 
 
II Buffers for polymerase chain reaction (PCR) 
 
10 x reaction buffer:                    100 mM Tris-HCl  
                                                     500 mM KCl 
                                                       15 mM MgCl2 
                                                     0.1% Gelatin, pH8.3 
                                    
Taq polymerase dilution buffer:    20 mM HEPES 
                                                     100 mM KCl 
                                                      0.1 mM EDTA, 1mM DTT 
                                                      10 % Glycerol 
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PCR stop buffer:          10 mM NaOH 
                                             1 mM EDTA  
                                       80 % Formamide  
                                      0.1 % Bromophenolblue 
                                      0.1 % Xylencyanol 
 
III Buffers for preparation of competent cells 
 
TFB I-Buffer:                  100 mM RbCl2 
                                          50 mM MnCl2 
                                          30 mM KOAc 
                                          10 mM CaCl2                             pH 5.8 
 
TFB II Buffer:                  10 mM MOPS 
                                         10 mMRbCl 
                                         75 mM CaCl2 
                                                             15 % Glycerol                           pH 7.0 
 
IV Buffers for DNA preparations 
 
(1) Buffers for genomic DNA isolation of human blood  
 
Nuclei Extraction Buffer: For 100 ml       10.95 g Sucrose  
                                                                   0.5 ml 1 M MgCl2  
                                                                   1  ml Triton X-100   
                                                                   1  ml 1 M Tris, pH 8.0 
                                                                  Filter sterile and store at 4°C 
 
DNA Extraction Buffer:  For 100 ml      4 ml 1 M Tris, pH 8.0 
                                                                 4 ml 0.5 M EDTA, pH 8.0  
                                                                 2 ml 5 M NaCl 
The nuclei extraction buffer and DNA extraction buffer are sterilized with filters and stored at 
4°C. 
 
(2) Buffers for plasmid DNA minipreparation 
 
Lysis Buffer I:     50 mM Glucose 
                            10 mM EDTA 
                            25 mM Tris-HCl 
                             2 mg/ml Lysozyme             pH 8.0 
 
Lysis Buffer II:    0.2 N NaOH 
                             1% (w/v) SDS 
 
Lysis Buffer III:   3 M Na-Acetate,                pH 4.8 
 
RNase A  :          10 mg/ml 
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Ribonuclease A is dissolved in 10 mM  Tris/HCl, pH7.5 / 15 mM NaCl, and 
heated for 15 min at 100°C. After slowly cooing down to room temperature, 
the solution is aliquoted and store at -20°C. 
(3) Buffers for  PAC and BAC  DNA  isolations 
 
P1(filter sterilized. store at 4ºC):                    15 mM Tris,pH8.0  
                                                                         10 mM EDTA ,pH 8.0  
                                                                         100 µg/ml RNase  A 
 
P2 (filter sterilized, store room temperature)   0.2 N NaOH  
                                                                         1 % SDS 
 
P3( autoclaved,store at 4ºC)                           3 M KOAc, pH5.5 
 
V Solutions for hybridization 
 
100 x Denhardt´s solution: For 1 l:               20 g  Ficoll 
                                                                      20 g   Polyvinylpyrrolidone  
                                                                      20 g   BSA 
 
Salmon sperm DNA:           5 mg/ml dH2O 
                           The solution is autoclaved for 10 min to shear DNA and stored at -20°C. 
 
Hybridization solution: For 1 l:               50 g Dextran Sulfate  
                                                                500 ml Formamide 
                                                                300 ml 20 x SSC 
                                                                  50 ml 20% SDS 
                                                                  50 ml 100 x Denhardt´s solution  
                                                                    4 ml  5mg/ml Salmon sperm DNA 
 
Prehybridization and hybridization  solution for oligo-hybridization:  
                   For 500 ml:                         150 ml 20 x SSC  
                                                                    5ml 100 x Denhardt´s solution  
                                                                2.5 ml 10% Sodiumpyrophosphate  
                                                              12.5 ml 20% SDS 
                                                                2.5 ml Salmon sperm DNA(5mg/ml) 
 
VI  Solutions for Southern blot 
 
Denaturing solution:     0.5 M NaOH , 
                                                                       0.5 M NaCl 
 
Neutralization solution:     0.5 M Tris-HCl, pH7.0  
                                                                         1 M NaCl 
 
VII      50 x TAE buffer:  2 M Tris-base, pH8.0 (adjust pH with acetic acid) 
                                                           50 mM EDTA-diNa 
        
 
VIII    10 x TBE buffer:  0.5 M Tris-HCl , pH8.0 
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           0.5 M Boric acid 
     0.5 M EDTA 
 
IX    20 x SSC buffer:    0.3 M Tri-sodium citrate, pH7.0 
3.0 M NaCl 
 
X       TE buffer :              10 mM Tris/HCl, pH7.6 
        1 mM EDTA-diNa 
 
XI     X-gal stock solution:               20 mg/ml in Dimethylformamide 
 
XII     Proteinase K solution :           1 mg/ml Proteinase K 
       0.5 M EDTA 
                 1% Sarcosyl 
 
XIII   1O x TAE DNA loading buffer:                  50 % (v/v) Glycerol 
                                                                                  0.25 % (w/v) Bromophenolblue 
                                                                                  0.25 % (w/v) Xylencyanolblue 
                                                                                  10 x TAE   
 
XIV   Ethidiumbromide stock solution:            10 mg/ml  dH2O 
 
2.4 Dideoxyribonucleic acids (DNA) 
 
Fish sperm DNA      Boehringer (Mannheim) 
Lambda DNA         New England BioLabs (Boston) 
 
2.5 Nucleotides 
 
Adenosine-5’-triphosphate-disodium (ATP)                         Boehringer (Mannheim) 
dNTPs                                                                                    Roth (Karlsruhe) 
 
2.6 Radioactive Labeled Substances 
 
α-32P-dCTP (∼3000 Ci/mmol)         Amersham (Braunschweig) 
γ-32P-ATP (∼3000 Ci/mmol)      Amersham (Braunschweig) 
α-33P-ddNTP (∼1000 Ci/mmol)     Amersham (Braunschweig) 
α-35S-dATP (∼1000 Ci/mmol)     Amersham (Braunschweig) 
 
2.7 Cloning Vectors 
 
pBluescript II KS (+)      Stratagene ( La Jolla, USA.) 
SuperCos 1        Stratagene ( La Jolla, USA.) 
The structures of vectors are given below. 
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2.8  Bacterial strains 
 
All bacteria used in this study were derived from Escherichia coli K12 strains 
XL1-Blue MR     recAl, endA1, gyrA96, thi-1, hsdR17,supE44,relA1, lac[F´proAB,lac Iq    
                            Z∆M15, Tn10, (Tetr)]c 
JM 83       F-, ara, ∆(lac-proAB), rpsL (StrR),( Φ80d∆(lacZ)M15) 
DH5α-MCR  F- mcrA∆(mrr-hsdRMS-mcrBC)φ80dlacZ∆M15∆(lacZYA-argF)  
 U169endA1 recA1deoR thi-1 phoA supE44λ-gyrA96 relA1 
DH10B   F-mcrA∆(mrr-hsdRMS-mcrBC)φ80dlacZ∆M15∆lacX74end A1 recA1 
 deoR∆(ara, leu)7697 araD139galU galK nupG rpsLλ- 
 
2.9 DNA length standards 
 
100 bp ladder(100-1000bp)                Invitrogen 
500 bp ladder (500- 8000bp)              Appligene-Oncor 
1 Kb ladder( 506-12216bp)                GibcoBRL (Eggenstein) 
50 Kb ladder (48.5-1000Kb)              Bio-Rad (München) and New England BioLabs (Boston) 
λ/Hind III (0.5-23Kb)                         New England BioLabs (Boston) 
 
2.10 Enzymes 
 
Restrictionendonucleases    New England Biolab (Boston) 
       Boehringer (Mannheim) 
       Gibcol/BRL (Eggenstein) 
       AGS (Heidelberg) 
Taq DNA polymerase    Institute of Human Genetics, Giessen 
T4 ligase      Boehringer (Mannheim) 
T4 polynucleotide kinase    Amersham (Braunschweig) 
Calf alkaline phosphatase (CIP)   Boehringer (Mannheim) 
Superscript II RNase H - reverse transcriptase Gibco/BRL (Eggenstein) 
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Proteinase K      Merck (Darmstadt) 
Lysozyme      Sigma (München) 
 
 
2.11 Kits 
 
Nonaprimer labelling kit     Appigene-Oncor (Heidelberg) 
T7 sequenase       Amersham (Braunschweig) 
Thermal sequenase for fluorescent labeled primers             Amersham (Braunschweig) 
Thermal sequenase for radioterminator cycle sequencing Amersham (Braunschweig) 
Nucleospin  extraction kit     Macherey-Nagel (Düren) 
Gigapack III Gold Packaging kit               Stratagene (La Jolla, USA) 
QIAamp RNA Blood Mini kit    Qiagen (Düsseldorff) 
 
2.12  Human genomic DNA library 
 
I.  Human PAC library : RPCI1 high density gridded filters  
 
The human PAC library RPCI1 provided by the UK HGMP Resource Center was constructed 
by Pieter de Jong and his group at the Roswell Park Cancer Institute, Buffalo. The library is 
constructed in vector pCYPAC2. The source of insert DNA is a normal male blood donor, and 
the average insert size is about 110kb. There are 25% clones in this library without inserts. 
The library consists of approximately 120,000 clones in 315 384-well microtitre plates and 
has been gridded in a 4 x 4 array on 22.2 x 22.2 cm Hybond N nylon membanes (Amersham). 
Each clone is spotted twice to give 36,864 spots on each membrane. The library consists of 7 
membranes. The structure of pCYPAC2 is shown below. 
 
 
 
 
Origin: http://bacpac.med.buffalo.edu/ 
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II. Human PAC library: RPCI6 high density gridded filters and DNA pools 
 
The human  PAC library RPCI6 provided by the Resource Center/Primary Database of the 
German Human Genome Project  was constructed by Pieter de Jong and his group at the 
Roswell Park Cancer Institute, Buffalo. It is constructed in the vector pPAC4 and E.coli 
DH10B is used as the host cell. The source of insert DNAs is a normal female blood donor, 
and the average insert size is about 140kb. The library consists of approximately 92160 clones 
in 240 384-well microtitre plates and has been gridded in a 5 x 5 array on 22 x 22 cm Hybond 
N+ nylon membanes. Each clone is spotted twice to give 27,648 spots on each membrane. The 
library consists of 4 membranes. The library is also available in DNA pools for PCR screens. 
The structure of pPAC4 is shown below. 
 
 
 
Origin: http://bacpac.med.buffalo.edu/ 
 
III.  Human chromosome 2 PAC library 
 
The library LL02NP04“AI“ provided by the Resource Center/Primary Database of the German 
Human Genome Project  was constructed by Gingrich. Digests of DNA from flow-sorted 
human chromosome 2 of  human-hamster hybrid somatic cell line GM10826 are cloned to 
vector  pCYPAC2 and  E.coli DH5 alpha MCR is used as the host cell. The library consists of 
approximately 5800 clones in 15 384-well microtitre plates, and has been gridded in a 3 x 3 
array on 22 x 22 cm Hybond N+ nylon membanes. Each clone is  spotted twice on one filter.  
 
IV. Human BAC library : RPCI-11 DNA pools 
 
The human BAC library RPCI-11 provided by Resource Center/Primary Database of the 
German Human Genome Project was constructed by Osoegawa  and Tateno at the Roswell 
Park Cancer Institute, Buffalo. It is constructed in vector pBACe3.6 and E.coli DH10B is used  
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as the host cell. The source of insert DNA is a normal male blood donor, and the average 
insert size is about 174kb. The pools consist of 442368 clones in 1152 plates. The library 
comprises 144 primary pools and represents approximately 25.3 fold genomic coverage. The 
structure of pBACe3.6 is shown below.  
 
 
 
 
 
 
 
 
Origin: http:// bacpac.med.buffalo.edu/ 
 
2.13 Patients 
 
A large German pedigree with AD-HSP was investigated. This family consists of 66 living 
members (see Figure 1) and the blood samples were collected from 42 participating members 
of the family. In addition, SPAST was sequenced in nine affecteds of small families with pure 
HSP. 
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3 Methods 
 
3.1 Isolation of DNA 
 
3.1.1 Isolation of  human genomic DNA from peripheral blood 
 
The blood  sample was mixed with an equal volume of cold PBS  and blood cells were 
collected by centrifugation at 1500 rpm for 10 min at 4°C. The blood cell  pellet  was first 
resuspended in 10-15 ml cold nuclei extraction buffer. The cell suspension was mixed with an 
additional 20-30 ml nuclei extraction buffer and placed on ice for 30 min. Cells were 
harvested by centrifugation at 2500 rpm for 10 min at 4°C and  resuspended in 500µl DNA 
extraction buffer. An equal volume of DNA extraction buffer containing SDS and proteinase 
K was added slowly and the solution was incubated at 50°C overnight. The DNA solution was 
stepwise extracted with an equal volume of  phenol, phenol/chloroform (1:1), and chloroform. 
The  aqueous  phase  was  separated  from  organic  phase  by  centrifugation  at  2500  rpm 
for 10 min. DNA was precipitated from the water phase with  ethanol (EtOH) and washed 
with 70% ethanol. DNA was dissolved in 500 µl TE containing RNase. The DNA solution 
was incubated  at 37°C for 30 min and  stored at 4°C. 
 
3.1.2 Isolation of plasmid or cosmid DNA 
 
Bacteria were harvested from 1.5 ml of overnight culture by  centrifugation  at 9000 rpm for   
1 min and resuspended in 100 µl Lysis buffer I. After addition of 200 µl Lysis buffer II, the 
cell suspension was incubated   on ice for 5 min and mixed with 150 µl Lysis buffer III. Cell 
lysates were separated by centrifugation at 13000 rpm for 10 min. The aqueous phase was 
extracted with  500 µl phenol/chloroform (1:1) and centrifuged at 13000 rpm for 5 min. DNA 
in the aqueous phase was precipitated with 1 ml EtOH at  -20 °C for 30 min and then 
collected by centrifugation at 13000 rpm for 10 min. The DNA pellet was washed with 200 µl 
70% EtOH and  air dried for 10 min. DNA was dissolved with 100 µl  TE buffer with RNase 
and stored at -20°C. 
 
3.1.3 Isolation PAC or BAC DNA  
 
Bacteria containing PAC or  BAC DNA were cultured in media containing kanamycin or 
chloramphenicol, respectively. Bacteria  were  grown as 1.5 ml culture for up to 16 hr at 37°C 
with vigorous shaking. Bacteria were harvested by  centrifugation at 3000 rpm for 10 min. 
The pellet was resuspended in 0.3 ml P1 solution, mixed with 0.3 ml P2 solution, and  placed 
at room temperature for 5 min. Cell lysates were mixed with 0.3 ml P3, incubated on ice for 5 
min, and cleared by centrifugation. The DNA from the aqueous phase was precipitated by 
addition of   0.8 ml ice-cold isopropanol and collected by centrifugation at 13000rpm for      
15 min at 4°C. The DNA pellet was washed with 0.5 ml of 70% EtOH and air dried at room 
temperature. When the color of DNA  pellet  turned  from white  to  translucent, DNA  was  
resuspended  in 40 µl  TE and stored at  -20°C. 
 
3.1.4 Isolation of YAC DNA 
 
Yeast were cultured in 30 ml  (-)Ura (-)Trp Yeast medium at 30°C for 2-3 days. Yeast cells 
were harvested by centrifugation  at 3000 rpm for 10 min and the pellet was washed with       
20 ml TE. The yeast cell pellet was resuspended in 500 µ1 of DNA extraction solution and 
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incubated at 50°C for 5 hr. The solution was stepwise extracted with 500 µ1 phenol, 500 µ1 
phenol/chloroform (1:1) and 500 µ1 chloroform. The aqueous phase was separated from the 
organic phase by centrifugation at 13000 rpm for 15 min. DNA was precipitated from the 
aqueous phase with 1 ml EtOH containing 50 µ1 3M NaOAc at -20°C for 30 min and  
collected by centrifugation. The  DNA pellet was dissolved in 500 µ1 TE. 
 
3.1.5 DNA extraction  from agarose gel slices 
 
Macherey-Nagel Nucleospin Extract kit was used to extract DNA from agarose gel slices and 
isolate PCR products from PCR reaction mixtures. 
The desired DNA fragment was excised from an agarose gel and mixed with 300 µl NT1 for 
each 100 mg agarose gel slices. The agarose gel slices in NT1 buffer were dissolved at 50°C 
for 10 min and then applied to a Nucleospin  Extract column. The DNA in solution was 
adsorbed to the  column during   centrifugation. The  column was washed with 600µl NT3 
buffer and 200 µl NT3 buffer. The DNA was eluted with 40 µl NE elution buffer by 
centrifugation. 
 
3.1.6  Purification of Polymerase Chain Reaction (PCR) Products 
 
PCR product (20 µl) was mixed with 80 µl NT2 buffer and applied to a Nucleospin Extract 
column. The spin column was centrifuged, the flowthrough discarded and the column was 
washed with 600 µl NT3 buffer then twice with 200 µl NT3 buffer. The DNA was eluted with 
40 µl NE elution buffer by centrifugation. 
 
3.2 DNA Quantitation 
 
Absorption (A) of the sample was measured at several different wavelengths to assess purity 
and concentration  of  nucleic acids. A260 measurement is quantitative for pure nucleic acid 
preparations in microgram quantities. The ratio of absorption at 260 and 280 nm was used as 
an indicator of nucleic acid purity. The spectrophotometer was set to zero at 260 nm by using 
TE buffer as a reference. The reference was removed and the DNA solution was  pipetted into 
the cuvette and read at 260 nm. The same procedure was performed at 280 nm. 
To determine the concentration (C) of DNA, the A260 reading was used in combination with  
the following equation:     Double-stranded DNA:   C (µg/ml) = A260 /0.020 
The value of  A260 / A280 > 1.8 indicated highly purified preparation of  DNA. Proteins that 
absorbed  at 280 nm reduced this ratio. 
 
3.3 DNA  gel  electrophoresis  
 
DNA molecules carry an overall negative electric  charge due to phosphate groups. 
Consequently, when DNA molecules are  placed  in an electric field they migrate towards the 
positive pole. Different sizes of DNA fragments can be separated  in a gel which is usually 
made of agarose or polyacrylamide. The gel matrix is composed of a complex network of    
pores through which DNA molecules must pass to reach the positive pole. The larger the 
DNA molecule, the slower it migrates through the gel. Thus, different sizes of DNA can  be  
separated through gel electrophoresis. Usually, agarose gels were used for separating  DNA 
fragments which were longer than 500 bp and polyacrylamide gels are used for those   
fragments shorter than 500 bp. 
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3.3.1 Agarose gel electrophoresis 
 
For 500 to 20 000 bp DNA fragments,  a range of  agarose gel concentrations from 0.5 to 2% 
(w/v) was usually used. The higher the agarose gel concentration, the better separation 
obtained  for smaller DNA fragments. The suitable gel concentrations for  separating different 
sizes of DNA fragments are listed in Current Protocol in Molecular Biology (Ausbel et al.46) 
and shown below. 
 
Agarose gel (%)                                      Separation of DNA fragments(kb) 
0.5                                                              1∼30 
          0.7                                                              0.8 ∼12 
         1.0                                                               0.5 ∼10 
         1.2                                                               0.4∼7 
         1.5                                                               0.2∼3 
 
Agarose gels were prepared as follows: 
Agarose was mixed with TAE buffer and boiled for 3 min. The melted gel solution was 
cooled down and  poured into a gel chamber. The comb was set  into the gel before the gel 
solution became solid. Electrophoresis was carried out in  TAE buffer. The DNA sample was 
mixed with loading dye before loading to the gel. The dye ran  as size indicator during 
electrophoresis. Usually, the voltage used for agarose gel electrophoresis was not more than 
100 V. The gel was stained in an ethidium bromide (EtBr) solution (∼2.4 µg/ml) for 15 min. 
The EtBr molecules intercalate with the DNA helix structure, and the EtBr-DNA complex is 
fluorescent under UV(λ=254 or 300 nm) irradiation allowing  DNA fragments on the gel to be 
visualized.  
 
3.3.2 Pulsed  field gel electrophoresis (PFGE) 
 
Pulsed field electrophoresis is a technique for resolving large DNA molecules up to 
chromosomes which are not able to be separated by a standard agarose gel electrophoresis.  
By changing the electric field between spatially distinct pairs of electrodes, megabase sized 
DNAs are able to reorient and migrate at different speeds through the pores in an agarose gel. 
According to the instruction manual of Bio-Rad CHEF-DR III system, there are several 
parameters influencing PFGE. 
a.  Agarose concentration: Gel concentration affects the size range of DNA molecules to be 
separated, and the sharpness or tightness of the bands. A 1.0% (w/v) agarose gel is useful 
for separation of  DNA molecules up to 3 Mb in size. Gel concentrations between 0.5 and 
0.9% are  useful for extremely high molecular weight DNA of greater than 3 Mb. For 
improving band tightness, 1.2- 1.5% agarose concentrations are used. However, running 
time increases  proportionately. 
b.  Buffer concentration and temperature: In PFGE, the mobility of the DNA is sensitive to 
changes in buffer temperature. It is recommended that the buffer is chilled to 14°C to 
maintain band sharpness and to dissipate heat generated during prolonged electrophoresis. 
Tris-Borate-EDTA (TBE) buffer at a concentration of 0.5x is commonly used. 
c.  Switch times: In PFGE, DNA molecules change direction or reorient themselves in the gel 
matrix according to the switches of electric field. Larger molecules take longer to reorient 
and therefore have less time to move during each pulse, so they migrate slower than 
smaller molecules. As DNA size increases, an increased switch time is needed to resolve 
DNA of different sizes. 
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d.  Voltage: DNA migration increases with increasing voltage. In general, lower voltage 
should be applied with increasing sizes. At high field strengths (6 V/cm), some very large 
DNAs (>3 Mb) can not be resolved on the gel and the voltage needs to be reduced. Some 
large DNA molecules do not enter the gels at high electric field strengths. Therefore, in 
selecting the field strength, a compromise between running time and resolution has to be 
made. 
e.  Field angle: Movement of DNA molecules up to 1 Mb is independent of the angle between 
90° and 120°. Decreasing the included angle will decrease the resolution of smaller DNAs 
by causing them to pile up on each other. The field angle should be decreased to less than 
120° when separating DNA fragments greater than 2 Mb. 
f.  Electrophoresis running time: The running time is determined by the migration rates of the 
DNA molecules. As the migration rate of the DNA decreases, the running time needs to be 
increased to adequately resolve the DNA fragments. 
 
3.3.2.1 Sample Preparation 
 
Large DNA fragments, such as YACs, are so fragile that they are sheared by mechanical 
forces during preparation. To avoid breakage of large DNA molecules, intact cells embedded 
in agarose were lysed and deproteinized in  agarose blocks.  
 
3.3.2.1.1 YAC  Plug  Preparation 
 
The method of yeast culture in medium was the same as described previously45. The cells 
were harvested by centrifugation. The pellet was washed with 20 ml TE followed by  20 ml 
SCE. The cells were collected by centrifugation at 3000 rpm for 10 min and  resuspended  in        
800 µl Yeast lysis buffer (8 mg lysozyme /ml SCE). The cell solution  was mixed with 800 µl  
1.5% LMP agarose in  SCE at  50°C. The mixtures were aliquoted to  each block on ice. The 
agarose blocks were transferred into 10 ml SCE containing 10 mM DTT and incubated at 
37°C for 60 min. The blocks were transferred  into 10 ml proteinase K solution and incubated 
at 50°C for 48 hr, following two washes of 15 ml TE for 15 min. The blocks were incubated 
in 10 ml TE containing 0.04 mg/ml PMSF at 50°C for 30 min and  washed two times with TE 
as described previously. The  blocks were stored in 20 ml 0.5 M EDTA pH 8.0 at 4°C. 
 
3.3.2.1.2 Liquid  Samples 
 
PAC and BAC DNA were digested with Not I before carrying out PFGE, the DNA solution 
can be directly loaded into the wells of the gel. In addition, using a thin well comb (0.75 mm) 
improved the resolution and sharpness of the bands. 
 
3.3.2.2 Parameters for PFGE 
 
Equipment: Bio-Rad CHEF-DR III system 
Running  buffer: 0.5 x TBE 
Gel: 1%  Agarose-Pulse Field in 0.5 x TBE buffer 
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                                                              YAC                                              PAC/BAC 
DNA                                               1/3 YAC plug                                    15 µl (∼100ng) 
Switch time                                     50→100 sec                                        1→20 sec  
voltage                                                  6 V                                                    5V 
Angle                                                   120°                                                  120° 
Time                                                    24hr                                                   22hr 
 
The PFGE was performed in 0.5 x TBE buffer at 14°C. The gel was stained for 30 min in   
500 ml 0.5 x TBE containing 100 µl EtBr (10 mg/ml) and destained for 10min in 0.5 x TBE. 
DNAs were visualized  by UV irradiation. YAC sizes were determined by using the 
chromosomes of Saccharomyces cerevisiae (strain YPH49) as size markers which range from  
260 kb to 2000 kb. BAC and PAC sizes were determined by using 50 kb size ladders (New 
England BioLabs) which range from 48.5 kb -1000 kb. 
 
3.3.3 Denaturing polyacrylamide gel electrophoresis 
 
Denaturing polyacrylamide gels can distinguish molecules differing in length by just a single 
nucleotide. In this study, denaturing polyacrylamide gels are used to separate the sequencing 
products and the PCR products which were amplified by different polymorphic markers. 
Denaturing gels were prepared as follows: 
After addition of 40 µl TEMED and 150 µl 10% APS, 60 ml of acrylamide gel solution was 
poured. The composition of  acrylamide gel solution is as follows. 
 
Components                                6% Polyacrylamide gel                  8% Polyacrylamide gel 
10 M Urea                                           375  ml                                         350  ml 
10 X TBE                                             50  ml                                           50   ml 
40% Acrylamide/bis-acrylamide          75  ml                                          100  ml 
                                                           total volume: 500 ml 
 
Electrophoresis: 
The gel was  prerun at 60 W  for  a minimum of 30 min. Samples were  denatured with  the 
loading buffer at 94 °C for 5 min before loading on the denaturing gel. Running time 
depended on the size of  the desired  DNA fragment using the loading dye as a size indicator. 
The relationship between gel concentration and dye mobility was adapted from Current 
Protocol in Molecular Biology and is shown below. 
___________________________________________________________________________ 
Polyacrylamide gel (%)          Migration of bromphenol blue          Migration of xylene cyanol 
                                                       (bases)                                                       (bases)_________ 
              6                                         26                                                            105 
              8                                         19                                                              75___________ 
 
After electrophoresis, the gel was dried on Whatman 3MM paper for 45 min at 75 °C on  a gel 
dryer and subjected to autoradiography. Autoradiography required a few hours to several days 
depending on the intensity of the signal. 
3.3.4 Single-stranded conformation polymorphism gel electrophoresis 
 
Single-stranded conformation polymorphism (SSCP) analysis was used to detect mutations 
based on   single-nucleotide changes in DNA sequences  that alter the mobility of single-
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stranded DNA in nondenaturing gels. The DNA fragments containing mutations were 
amplified using  polymerase chain reaction (PCR) and rendered single-stranded by heating in 
a denaturing buffer. The denatured strands were separated on polyacrylamide gels under 
conditions that resolve two molecules by conformational changes caused by differences in as 
little as one base. 
 
SSCP  gels were prepared as follows: 
___________________________________________________________ 
For  0.5 x MDE  gel                                  15 ml          2 x MDE gel solution 
                                                                 3.6 ml         10 x TBE buffer 
                                                                41.4 ml         dH2O  
____________________________________________________________ 
 
The gel solution was mixed with  500 µl APS and 50 µl TEMED and allowed to polymerize. 
The electrophoresis was carried out  in 0.6 x TBE . 
 
Electrophoresis: 
The desired DNA fragments were amplified by a standard PCR procedure incorporating      
[α-P32] dCTP in the amplified fragments. PCR stop buffer was added to 20 µl of PCR product 
and samples were denatured at 90°C for 3 min before loading on a 0.5 x MDE gel. 
Electrophoresis  was carried out at 400 V at 4°C overnight. The gel was dried and subjected to 
autoradiography. 
 
3.4 Enzymatic manipulation of DNA 
 
3.4.1 Digestion of DNA with restriction endonucleases 
 
Restriction endonucleases are isolated from bacteria and can recognize short DNA sequences 
and cleave double-stranded DNA at specific sites within or adjacent to recognition sequences. 
The amount of enzyme, DNA, buffer and ionic concentration, and the temperature and 
duration of the reaction  were adjusted according to different applications. 
  
3.4.1.1 Single digestion 
 
 Single digestion refers to digesting a single DNA sample with a single restriction 
endonuclease. A total of  20 µl reaction including 0.1~ 4 µg DNA, 1 to 5 U restriction 
endonuclease /µg DNA and specific buffer concentration was convenient for analysis by gel 
electrophoresis. The reaction was incubated at  37°C for 1.5-2 hr and stopped at 70°C for 10 
min. The volume of restriction  endonucleases was not more than 1/10 the reaction volume 
because glycerol in enzyme buffer can  interfere with the reaction.  
 
3.4.1.2 Double digestion 
 
 Double digestion refers to digesting a  single DNA sample with two different restriction 
enzymes. Many restriction endonucleases are active in a wide variety of buffers, so it is  
usually possible to choose a standard buffer in which two enzymes can  retain  their activities. 
Alternatively, DNA can be first digested with the restriction enzyme in low salt buffer 
followed by the adjusting the reaction mixtures to a high salt condition and digested with the              
other enzyme. 
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3.4.1.3. Restriction endonuclease digestion of YAC plugs 
 
To cleave the desired DNA fragments from YAC plugs, it was necessary to treat the YAC 
plugs before restriction enzyme digestion.  One YAC DNA plug was cut into three slices and  
the slices were washed twice with  TE for 30 min. The slice was mixed with  60 µ1 dH2O and    
10 µ1 10 x restriction enzyme buffer and dissolved  at 70°C for 20 min. The sample was 
cooled down to 37°C and 15-30 U of restriction enzyme were added. The reaction was 
incubated at 37°C for 1.5-2 hr. 
 
3.4.2 Dephosphorylation of DNA with calf intestine phosphatase (CIP) 
 
Calf intestine phosphatase catalyzes the hydrolysis of 5’-phosphate residues from DNA, and 
therefore can  be used to prevent self-ligation of cloning vector termini. The CIP reaction 
conditions for dephosphorylation of DNA were as follows: 
____________________________________________ 
   10 x CIP buffer                                                  5     µl 
   dH2O                                                               14.5  µl 
   Vector-DNA(0.5-1.0 pmol /µl)                       30     µl 
   CIP (20 U/µl)                                                    0.5  µl 
____________________________________________ 
                                           total volume:            50 µl 
The reaction was incubated at 37°C for 1 hr and stopped at 75 °C for 10 min. The 
dephosphorylated DNA was precipitated with ethanol as described previously. 
 
3.4.3 Preparation of blunt ends by repairing of 5’ Overhangs with Klenow Fragment 
 
If the 5’ termini of vector and insert DNAs were incompatible, both could  be modified with 
Klenow fragment to generate blunt ends for ligation. The reaction conditions are as follows: 
_______________________________________________ 
    DNA (1-2 µg)                                             15    µl 
    10 x reaction buffer                                      2.5  µl 
     dH2O                                                           2.5  µl 
     dNTP mix (125µM)                                   4      µl 
     Klenow-polymerase (1-5U)                        1      µl______ 
                                               total volume: 25 µl 
The reaction was incubated at  room temperature for 20 min and stopped at 75°C for 10 min. 
The DNA was precipitated with ethanol. 
 
3.4.4 Ligation of DNA with T4 DNA ligase 
 
T4 ligase, originally isolated from phage T4, catalyzes the formation of phosphodiester bonds 
between 5’ phosphate and 3’ hydroxyl termini in duplex DNAs. Using ATP as a cofactor, T4 
DNA ligase catalyzes the repair of  single-stranded nicks in duplex DNA and join duplex 
DNA restriction fragments with either blunt or sticky ends. The standard reaction conditions  
are  as follows: 
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____________________________________________ 
Vector DNA (100 ng/µl)                                 1 µl 
Insert DNA (100 ng/µl)                                  4 µl 
10 X ligation buffer                                        1 µl 
dH2O                                                              3 µl 
T4 DNA ligase                                                1 µl______ 
                                          total volume:     10µl 
Ligation was performed  at 16°C for 16 hr and  stopped by incubation at 75°C for 10 min. The 
ligation product was ready for transformation. The pBluescript II KS (+) was used as a vector 
in this study to ligate CAG positive fragments subcloned from a cosmid library. 
 
Another method  is used when  insert DNA is embedded in low melting point (LMP) agarose 
gel. The procedure is as follows: 
An agarose slice containing the desired DNA fragment was excised from a 0.7% LMP gel. 
The excised agarose volume should not be  more than 20 µl. The agaraose slice was dissolved 
in 60 µl dH2O at 70°C for 10 min until the agarose slice was dissolved. The agarose 
concentration was less than 0.2% in the solution. The sample was incubated at 32°C and 
added with 1 µl vector DNA (100 ng), 8 µl 10 x ligation buffer, 2 µl 10 mM ATP, 1 µl T4 
DNA ligase. Ligation was performed at 32°C overnight and stopped by incubation at 75°C for 
10 min. The ligation product was ready for transformation. 
 
3.5 Transformation of E.coli cells with plasmids 
 
3.5.1 Preparation of Competent Cells 
 
A single colony of  E. coli ( JM83 or XL1-Blue)  from a freshly streaked LB agar plate was 
transferred into 50 ml LB medium followed by incubation at 37°C overnight with vigorous 
shaking. A 100 µl aliquot of the bacterial culture was transferred to 100 ml dYT medium and 
incubated at 37°C with shaking until the  bacterial concentration reached 5 x 107 cells/ml 
(O.D≅0.5). Bacteria were collected by centrifugation at 2500 rpm at 4°C for 10 min. The cell 
pellet was resuspended in 15 ml TBF I and incubated on ice for 60 min. Bacteria were 
collected by centrifugation  at 2500 rpm at 4°C for 10 min and  resuspended in 2 ml TBF II. 
Competent cells were aliquoted and stored at -70°C. 
 
3.5.2 Transformation  
 
Competent cells were thawed on ice for 5 min.  Plasmid DNA was  mixed with the competent 
cells, the mixture was incubated on ice for 15 min followed by heat shock at 45°C for 90 sec 
in a water bath. A 200 µl aliquot of dYT was added to the cells followed by incubation at 
37°C for 45 min. Cells were spread on the LB-antibiotics agar plates and incubated  at 37°C 
overnight. 
 
3.6 Southern Blotting 
 
Southern blotting is the transfer of DNA fragments from an agarose gel to a membrane via 
upward capillary transfer of a high-salt buffer and subsequent hybridization with a 
complementary probe. The transfer results  in immobilization of the DNA fragments so that 
the  membrane  carries  a  semipermanent   copy  of  the  banding  pattern  of  the  gel.   After  
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immobilization, the DNA can  be used for hybridization analysis which facilitate 
identification of bands with a sequence identical to a labeled probe. 
 
DNA fragments were separated by agarose gel electrophoresis, denatured in denaturing 
solution for 1 hr, and  soaked for 45 min in a neutralization solution. The blotting apparatus 
was set up in a chamber containing 20 x SSC and Whatman 3 MM paper saturated with        
20 x SSC. The gel was turned upside down on the saturated Whatman 3 MM paper. The 
blotting membrane (Hybond N/N+) was laid exactly on the gel. Two sheets of Whatman 3 
MM paper were placed on the blotting membrane. Additional paper towels were placed on the 
Whatman 3 MM paper.A 500 g weight was placed on top of this pile of papers and transfer of 
the DNA to the membrane was allowed to proceed overnight. The blotting membrane was  
labeled at the well edges and baked in a vacuum oven at 80°C for 2 hr.  
 
3.7 Hybridization 
 
The principle of hybridization is that a single-stranded DNA or RNA molecule (the so-called 
probe) can  bind to a single-stranded DNA or RNA with a complementary sequence. The 
stability of the hybrid depends on the extent of the base pairing and base composition. In 
practice, a labeled probe is  used to hybridize the target DNA that has been immobilized on a 
membrane.  Hybridization analysis is usually performed with a radiolabeled DNA probe   
(100-1000 bp) and are sensitive enough to detect single-copy genes in complex genomes. 
 
3.7.1 DNA probe preparation 
 
3.7.1.1 Random primers  labeling 
 
Appligene-Oncor Nonaprimer labeling kit was used for random prime labeling and 
purification. A 1 µl aliquot of human genomic DNA (∼300 ng) was mixed with 6 µl dH2O and 
denatured at 95-100°C for 10 min. The denatured DNA was  chilled on ice for 5 min and 
mixed with 4 µl Nonaprimer mix, 3 µl dATP/dTTP/dGTP (1:1:1), 5 µl [α-P32]dCTP and 1 µl 
Klenow enzyme. The reaction mixture was incubated at 37°C for 30 min. The  [α-P32]dCTP  
labeled DNA fragments were mixed with 60 µl adsorb solution and 2 µl DNAprep resin. The 
resin was centrifuged and washed twice with 100 µl wash solution. The labeled DNA 
fragments were eluted thrice with 100 µl elution solution. 
 
3.7.1.2 5´-end labeling of oligonucleotides 
 
The reaction mixture composed of 1 µl (15 pmol/µl) oligonucleotide, 1 µl 10x reaction buffer, 
4 µl [γ-P32 ]ATP, 2 µl dH2O and 2 µl (1:10 diluted) T4 polynucleotide kinase incubated  at 
37°C for 1 hr. The reaction was  stopped at 65°C for 10 min. The oligonucleotide  was  
precipitated  by  a  solution  containing 30 µl  EtOH,1 µl Glycogen and 1.1 µl 3 M NaOAc at -
20°C for 30 min. The oligonucleotide was collected by centrifugation, washed with 70% 
EtOH  and  dissolved in 100 µl  TE. 
 
3.7.2 Prehybridization and hybridization 
 
The membrane was prehybridized  in   prehybridization solution (≥ 1 ml /10 cm2 membrane)  
at 42°C for at least 4 hr. The DNA probe was denatured at 94 °C for 10 min and added to 
hybridization solution. The membrane was transferred to the hybridization solution and 
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incubated  at 42 °C overnight. The membrane was  stepwise washed by increasing washing 
stringency. The procedures were as follows: 
 
___________________________________________________________________________ 
Washing buffers                 Temperature                  Time 
4 X SSC                         room temperature             3 x 15 min 
2 X SSC/0.5% SDS                 45°C                             20 min 
1 X SSC/0.5% SDS                 45°C                             20 min  
0.5 X SSC/0.2% SDS              60°C                             30 min 
0.2 X SSC/0.5% SDS              60°C                             30 min 
0.1 X SSC/0.1% SDS              60°C                             30 min__________________________ 
 
The radioactive signals were controlled with Geiger counter to avoid an over stringent wash. 
The membrane was packed in plastic wrap and  subjected to autoradiography. 
 
3.8 Polymerase chain reaction (PCR) 
 
PCR  is  a rapid method for in vitro amplification of a specific fragments of DNA. The basis 
of PCR is that primers hybridize to DNA templates and then DNA polymerases synthesize the 
DNA segments between two primers from 5’→ 3’. These products accumulate with each 
subsequent cycle of denaturation, annealing to primers, and amplification. If n cycles of PCR 
are carried out,  2 n-2 fold amplification of  product can be synthesized. PCR was performed in 
1x PCR buffer containing 0.25 M of each dNTP, 0.5 µM of forward/reverse primers, 2.5 U 
Taq polymerase and 30 ng genomic DNA in a reaction volume of 20 µl. The standard PCR 
conditions were 30 cycles at: 94 °C for 30 sec, 45-65°C for 60 sec, and  72°C for 15 sec. The 
reaction was preceded by 5 min denaturation at  94 °C and followed by a final extension at 
72°C for 5 min. To incorporate [α32P]-dCTP into the PCR product during strands synthesis, a 
modified dNTP mix was used. The modified dNTP mix contains less dCTP (0.1 mM) and the 
concentration of dATP, dGTP and dTTP is unchanged. In this case, 0.1 µl [α32P]-dCTP is 
used in a 20 µl PCR reaction and the other components of PCR are the same as described 
above. 
 
3.9 Reverse transcriptional polymerase chain reaction (RT-PCR) 
 
3.9.1 Total RNA isolation from human blood 
 
QIAamp RNA Mini kit was used for isolation of total RNA. Human blood (2 ml) was mixed 
with 10ml buffer EL and  incubated for 15 min on ice. Blood cells were collected by 
centrifugation at 400 x g for 10 min at 4°C. The cells pellet was resuspended into 4 ml buffer 
EL and repelleted. Pelleted leukocytes were resuspended into 600 µl buffer RLT containing    
β-mercaptoethanol. Lysates were transferred into a QIA shredder spin column and  
homogenized by centrifugation for 2 min at maximum speed. The homogenized lysates were 
mixed with 600 µl 70% ethanol and  transferred  into a new QIAamp spin column. The    
nucleic acids were adsorbed to the column by centrifugation for 15 sec at ≥8000 x g. The 
QIAamp spin column was washed with 700 µl buffer RW1 followed by 500 µl buffer RPE 
containing ethanol. RNA was eluted twice with 30-50 µl RNase-free water and  stored at          
-80°C. 
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3.9.2 First strand cDNA synthesis and RT-PCR 
 
An 11 µl aliquot of total RNA (1-5 µg) was mixed with 1 µl Oligo (dT)15 (500µg/ml) and 
heated at 70°C for 10 min. To the mixtures of RNA and Oligo (dT) 4 µl 5x first strand buffer, 
2 µl 0.1 M DTT and 1 µl 10 mM dNTP mix were added. This mixture was first incubated at 
42°C for 2 min before the addition of 1 µl (200 U) SUPERSCRIPT II. The cDNA synthesis 
reaction was  incubated at 42°C for 50 min and  inactivated at 70°C for 15 min. The cDNA 
was ready for PCR amplification. The standard PCR procedure was performed by using 1-2 µl 
cDNA as template. The primers for amplifying  SPAST cDNA  are listed. 
 
Table 3. Primers used for SPAST cDNA amplification and sequencing 
_________________________________________________________________
Primer Sequence (5'->3') Tm (oC) Product size (bp) 
_________________________________________________________________________
SPA_Db TAGCAGTGGCTGCCGCCGT 62 655 
SPA_Dm AAGCGGTCCTTGGCCATAAC   
    
SPA_Dc GGCGGCAGTGAGAGCTGTG 60 543 
SPA_Dn CTAGCTCTTTCACACTGTTC   
    
SPA_Ad AACAGGCCTTCGAGTACATC 60 746 
SPA_Am CTGTGAACAACTCAGGCCTC   
    
SPA_Ba CTACAACTGCTACTCGTAAG 58 763 
SPA_Bm CAGTGCTGCATCTTTTGCC   
    
SPA_Ca TGGAGATGACAGAGTACTTG 56 766 
SPA_Cm CTGGAATACTTTCATCTGC   
_________________________________________________________________
The primers are adapted from the database of Genoscope, Centre National de Squenage, 
France.( http://www.genoscope.cns.fr/)__________________________________________ 
 
3.10 DNA sequencing 
Chain termination (or the Sanger method) is  the most commonly used technique for 
sequencing DNA. All reagents needed for in vitro DNA synthesis are combined in this 
reaction, including a DNA polymerase and a 2’, 3’-dideoxynucleotide (ddNTP). ddNTPs can 
be incorporated by DNA polymerases into growing DNA chains through 5’ phosphate groups. 
However, the 3’-OH group necessary for phosphodiester bond formation and chain elongation 
is lacking so the chains terminate at the exact point at which the ddNTP is incorporated.  Four 
sets of reactions are  performed on each template, differing only by ddNTPs species. The 
dNTP:ddNTP ratio is selected so that the resulting labeled strands formed a nested set of 
molecules up to several thousand bases long, each terminating at a specific base. These are 
able to be separated according to size by denaturing acrylamide gel electrophoresis.  
 
3.10.1 Sequencing plasmid DNA with thermo sequenase fluorescent labeled primer  
           cycle sequencing kit  
 
In this study, a thermo sequenase fluorescent labeled primer cycle sequencing kit was used to 
sequence the subcloned DNA fragments derived from the cosmid library. 
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To denature the template DNA, 10 µ1 plasmid DNA (∼2.0µg) was mixed with 2 µl 2 M 
NaOH and incubated at room temperature for 10 min. The denatured DNA was precipitated 
with EtOH and  dissolved in 23 µl sterile d H2O. 
Two common primers, M13 and reverse primers, were used to sequence the insert DNA 
cloned into pBluescript II KS (+). The sequences of primers are as follows: 
     M13(-20) primer: 5’-GTAAAACGACGGCCAGT -3’ 
     Reverse  primer :  5’-GGAAACAGCTATGACCATG-3’ 
The sequencing mixture comprising 1 µl DMSO and 1.5 µl fluorescent labeled primer           
(1 pmol/µl) was  mixed with denatured  23 µl of plasmid DNA solution. Aliquots of 6 µl of 
this mixtures were mixed with 2 µl  of reagents A, C, G, T, respectively. Cycle sequencing 
conditions were 30 cycles at 94°C for 15 sec, 60°C for  15 sec, and  at 70°C for 15 sec. After 
cycle sequencing, 4 µl stop buffer were added to each reaction and samples were denatured at 
90°C for 5 min. The samples were loaded on a 4% denaturing acrylamide gel. Sequences were 
analyzed by MWG CL4200 autosequencer. 
 
3.10.2 Sequencing PCR product with thermo sequenase radiolabeled terminator 
           cycle sequencing kit 
 
A thermal sequenase radiolabeled terminator cycle sequencing kit was used to sequence all 17  
exons, 5’ UTR,  3’-UTR , intron 6, intron 10, and intron 11 of the SPAST gene. Each fragment 
was amplified by PCR and purified after agarose gel electrophoresis with a Nucleospin 
extraction kit.  
 
In the cycle sequencing reactions [α-33P]ddNTPs were used as terminators. The sequencing 
reaction was performed according to the manufacture instructions. The cycle sequencing 
conditions were 30 cycles at 94°C for 30 sec, Tm for 30 sec, and  72°C for 90 sec. Tm was 
dependent on the sequencing primer used. The cycle sequencing products were loaded on a 
denaturing polyacrylamide gel and the sequences were  read on  an autoradiograph. The 
sequence and Tm of primers for amplification and sequencing of the various portions of 
SPAST gene are listed. 
 
Table 4. The primers for amplification and sequencing of SPAST. 
___________________________________________________________________________ 
Location Primer Sequence (5'->3') Tm (oC)     Product size 
          (bp) 
___________________________________________________________________________ 
5' UTR spg4utr5af GCCTTTGCGGTCTGGGTTCTGTGC 64 661 
 spg4utr5ar GGCTTGGGGTCGCTCTGCTGGTTC  
   
 spg4utr5bf GGTCGCCTGGCAGAAAAAGAT 62 748 
 spg4utr5br CAAACAGCGGGTAGGAGAAATAGT  
   
exon1 spgex1pza GCCACCGACTGCAGGAGGAGAAGG 65 721 
 spgex1pzb CCGCAGAAAAGGGACGCAGGTGTT   
    
 spgex1pbf GTCGGTCTGCGGGAGGCGGGTTAT 65 705 
 spgex1pbr TGTGGGGGAAGGCTGGTGTCTGAA   
_________________________________________________________________________________
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_________________________________________________________________________________  
exon2 spgex2pf TTTTTATGTATTACCTCTCAA 45 266 
 spgex2pr AAAAATAAATAAATAAATAAATAG   
    
exon3 spgex3paf CTTTCTTTTGGGTATACATTTTCT 55 340 
 spgex3par AGCAAGCGTCCATCTCAA   
    
exon4 spgex4paf ATTTCTGTTATTTTCGTGACT 54 335 
 spgex4par ATGCAAGCTTTATTATTTTATG   
    
exon5 spgex5pf CCTATGAAGATCCTGGTAC 56 806 
 spgex5pr TTTTATAGCAAGTTGCCCTG   
    
exon6 spgex6pbf TCTCTAGTGAATACAGTTTTACC 60 552 
 spgex6pbr ACAGGGCCCAGTTATTACAA   
    
intron6 spgin6pf TTAAGGGTACTCCGAAAAC 54 457 
 spgin6pr GACCAGCTATATCATCAAAT   
    
exon7 spgex7paf ACTGGGCCCTGTTTGTAT 55 352 
 spgex7par TATCCATTTTCCTATTCTAT   
    
exon8 spgex8pf CTGTTTGGGAAGATGCT 53 273 
 spgex8pr GTAAATAATAGACTCAAGGACAAG   
    
exon9 spgex9pf TGGCCTCATAGCTTACATTTTTAG 55 315 
 spgex9pr CCAGCCAGTTTACGGTATTTTATT   
    
exon10 spgex10pf GTAGTACTCTCCCCTTTCTCA 55 307 
 spgex10pr TAATGTTTCCAATCGTATCTT   
    
intron10 spgin10pf GTAGTACTCTCCCCTTTCTC 60 505 
 spgin10pr TGCTCCCCTTCTCTTCTTTCAC   
    
exon11 spgex11pf ACTCACATAGCTTGGTCTT 55 418 
 spgex11pr CATGAGTAAATATTGTCTGTAA   
    
intron11 spgin11pf AGACGCCTAAAAACTGAAT 52 482 
 spgin11pr TTGCCTAAAACCGTAACTA   
    
exon12 spgex12pf ATGGCCAAGGTTAAAAATACAA 54 281 
 spgex12pr CTGGAAGAAAATAGTGAAT   
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exon13 spgex13pf CTTTTCCTGTCATTTGCTGTTT 60 311 
 spgex13pr CATTTTTGTTTCTCTGGGGTAA   
    
exon14 spgex14paf GGAGGCTGAGATGGGAGGATT 60 406 
 spgex14par AAGGCAAAGGAGGTAGAGGATGAG   
    
exon15 spgex15paf AAAAAGCGGGAGGGGAAATA 60 328 
 spgex15par GAAGGCTGGGTGGGAGAATCA   
    
exon16 spgex16paf TTCAACTGCAAAATGTATGTA 54 250 
 spgex16par ATGGTGAAATGCCCTCTC   
    
exon17 spgex17p1f ATAACATTAAGAAACAGCAGCATC 60 845 
 spgex17p1r AAAAGGTAAAAAGAACACAACAAT   
    
 spgex17p2f AATTGTTGTGTTCTTTTTAC 50 745 
 spgex17p2r TGACATTTTACATAGCATC   
    
 spgex17pe GGAATGCCAAACACTCTT 53 312 
 spgex17pf AAAAATACTGCAGGTCACAT   
   
3' UTR spg4utr3af ATAACATTAAGAAACAGCAGCATC 62 850 
 spg4utr3ar AAAAGGTAAAAAGAACACAACAAT   
    
 spg4utr3bf AATTGTTGTGTTCTTTTTAC 50 747 
 spg4utr3br TGACATTTTACATAGCATC   
    
 spg4utr3cf GGAATGCCAAACACTCTT 53 313 
 spg4utr3cr AAAAATACTGCAGGTCACAT   
___________________________________________________________________________ 
Note: The sequences are adapted from the database of Genoscope, Centre National de 
Séquençage, France ( http://www.genoscope.cns.fr/). The primers are designed according to 
the sequence of the exons including at least 30 nucleotides of the preceding and followed 
introns. 
 
3.10.3 Sequencing DNA with a T7 sequenase kit 
 
A T7 sequenase kit was used to prepare a basewise size ladder by using  phage DNA M13 as a 
template. The preparation was as follows:  
Master mix A was composed of  20 µl DNA (1∼2µg), 4 µl primer (4 ng/µl) and 4 µl     
annealing buffer. Master mix B was composed of  3.6 µl dilute  buffer, 6.5 µl label-mix,        
1.6 µl 35S dATP and 0.4 µl T7 polymerase. Master mix A was first incubated at 60°C for        
10 min then at room temperature for 10 min. Master mix A and 12 µl Master mix B were   
mixed and  placed at room temperature for 5 min. Aliquots of  9 µl of this mixture were added 
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to 5 µl ddATP, ddCTP, ddGTP, and ddTTP. This reaction was incubated  at 37°C for 5 min 
and stopped with 10 µl stop buffer at  90°C for 3 min . 
 
3.11 Cosmid library construction 
 
Cosmid vectors are valuable tools for isolation and physical mapping of large fragments of  
DNA ranging in size from 10 to 42 kb. SuperCos is a cosmid vector containing bacteriophage 
promoter sequences flanking a unique cloning site. It has been engineered to contain genes for  
amplification and expression of cosmid clones in eukaryotic cells. In addition, most genomic 
inserts can be excised as a single large restriction fragment using the Not I restriction site that 
flanks the SuperCos 1 polylinker. 
 
3.11.1 Preparation of host cells 
 
XL1-Blue MR was used as the host cell and its genotype was previously described in Material 
section. A single colony of XL1-Blue MR was inoculated  in  50 ml NZYC medium and 
incubated at 37°C overnight. The host cells from 10 ml culture were harvested by 
centrifugation at 2500 rpm for 15 min and resuspended into 25 ml 10 mM MgSO4 . The host 
cells were stored for up to 2 days at 4°C. 
 
3.11.2 Preparation of a  -80°C  glycerol stock 
 
A 10 ml aliquot of LB medium was inoculated with a single colony of host cells and 
incubated at 37°C for 6-8 hr. The cells culture was mixed with 4.5 ml solution of a sterile 
glycerol-LB (1:1) medium. The mixtures were aliquoted and stored at -80°C. 
 
3.11.3 Preparation of vector DNA 
 
SuperCos 1 vector  (∼85 µg)  was  restricted with 5 µl Xba I (20 U/µl) in a total of 100 µl 
buffer H at 37°C for 2 hr. The linear SuperCos 1 vector is about 7.6 kb. The volume of the 
digestion reaction mixtures was adjusted to 200 µl with  TE. The solution  was extracted with 
200 µl phenol/chloroform (1:1) and chloroform. The DNA was precipitated with 500 µl EtOH 
containing 25 µl 3M NaOAc pH5.5 at -20°C for 30 min and  collected by centrifugation. The 
pellet was washed with 70% EtOH and air dried. The DNA was dissolved in 20 µl 1x 
dephosphorylation buffer. The Xba I cut vector DNA was dephosphorylated with 2µl CIP (10 
U/µl) at 37°C for 90 min and extracted with phenol/chloroform as described above. The DNA 
was dissolved with 74 µl 1X buffer B. The vector was  restricted with 6 µl BamH I (20 U/µl) 
at 37°C for 2 hr. The two DNA fragments are 1.1 and 6.5 kb. The DNA was extracted with 
phenol/chloroform and dissolved in 20 µl TE. The restricted  vector was stored at -20°C. 
 
3.11.4 Partial digestion of YAC DNA 
In order to clone DNA fragments into the BamH I site of the SuperCos 1 cosmid vector, the 
YAC DNA was partially digested with Sau 3A. An optimal concentration of Sau 3A for 
obtaining appropriate partial digestion products was previously determined. 
 
The YAC DNA agarose plug was washed twice with TE and dissolved in 120 µl 1x buffer A 
at  70°C. Sau 3A (0.03 U/µl)  was added to the solution and incubated at 37°C for 15 min. The 
reaction was stopped at 70°C for 10 min. The partially digested DNA was dephosphorylated 
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with 5µl CIP at 37°C for 60 min. The DNA was extracted with phenol/chloroform, 
precipitated with EtOH /0.3 M NaOAc pH 5.5, and  dissolved in 12 µl  TE.  
 
3.11.5 Ligation 
 
The reaction mix was composed of  12 µl partially digested YAC DNA [Sau 3A-CIP], 3 µl         
(1 µg/µl) SuperCos 1 DNA  [Xba I-CIP/BamH I], 2µl 10x ligase buffer, and 2 µl 10 mM ATP 
and 1 µl  T4 DNA ligase. The ligation mixture was incubated in a water bath at 32°C 
overnight.  
 
3.11.6 Packaging 
 
The packaging extracts (Gigapack III Gold Packaging Extract; Stratagene) were quickly 
thawed at room temperature until the contents of the tube began to thaw. The ligation product 
was  added immediately to the packaging extract and  stirred gently with a pipette tip. The 
packaging mixture  was spun quickly for 5 sec and incubated at room temperature (∼20°C) for 
2 hr. To the mixture 470 µl SM buffer and 10 µl Chloroform were added. The cosmid library 
was ready for titering and could be stored  at  4°C for 1 month. 
 
3.11.7 Titration of  the cosmid packaging reaction 
 
The cosmid library was diluted 1:10 and 1:50 in  SM buffer. The diluted cosmid library (25µl) 
was mixed with the equal volume of  host cells in 10 mM MgSO4 and incubated at room 
temperature for 30 min. Host cells were regrown in  200 µl dYT at 37 °C for 60 min and  
collected by centrifugation  at 9000 rpm for 1 min. The cell pellet was resuspended in 50 µl 
LB medium. The cell suspension was spread on LB-Amp agar plates and incubated at 37 °C 
overnight. The colony forming units per milliliter (cfu/ml) were estimated. 
 
3.11.8 Screening  the cosmid library 
 
The titer of the cosmid library was determined by serial dilution as described above. The 
appropriate amount of host cell suspension for plating was calculated and the suspension was 
diluted and ∼104 cfu was spread on the LB-Amp plates (10 x 15 cm in diameter petri dish). 
The plates were  incubated at 37°C overnight. Hybond N/N+ Nylon membranes (15 cm in 
diameter) were used to perform colony lifts. Host cells  were regrown on LB-Amp plates at  
37 °C for 4-6 hr until the bacterial colonies began to reform and then stored at 4°C. Colony lift 
and hybridization on Nylon membranes were prepared as follows. 
The  membranes  were placed  colony-side  up  for 10 minutes  on  the  surface of Whatman 
3 MM paper prewetted with 0.5 M NaOH and transferred to a sheet of Whatman 3MM paper 
prewetted with 1 M Tris-HCl (pH 7.6) for 10 min. Membranes were transferred to a sheet of 
Whatman 3 MM paper prewetted with 1 M Tris-HCl (pH 7.6) and 1.5 M NaCl for 15 min. 
Cells debris were  removed by carefully brushing the membranes in the solution of    1 M  
Tris-HCl  (pH 7.6)  and 1.5 M NaCl. The membranes were air dried and baked at 80°C for     
2 hr.  
Prehybridization and hybridization were performed at 42°C. The membranes were washed 
with 4 x SSC, 0.5% SDS buffer followed by washes of increasing stringency until the 
background diminished. The membranes were packed with plastic wrap and subjected  to      
autoradiograhy. 
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3.11.9 Purification of  the positive clones 
 
The autoradiograph and original host plate were aligned. The positive candidate colonies were 
transferred in array to a new LB-Amp plate and  incubated at 37°C overnight. The selective 
colonies were  rescreened by hybridization as described previously46. A 4 ml aliquot of LB-
Amp medium was inoculated with each positive clone and incubated at 37°C overnight. The 
bacterial culture  was  used  for  isolating  the cosmid  DNA as described previously  and the 
remaining  1 ml culture was used for preparation of glycerol stock. 
 
3.12 YAC contig construction 
 
3.12.1 Yeast artificial chromosome (YAC) 
 
A total of 26 YACs were chosen by searching databases, the Whitehead Institute for Genome 
Research (http://www-genome.wi.mit.edu/), Genethon (http://www.genethon.fr/genethon-
en.html), and the previously reported YAC contig (De Jonghe et al.84) and  obtained from 
CEPH (Centre d’Etude Polymorphisme Humain, Paris, France). The YAC clones were plated 
on (-)Ura, (-)Trp agar plates  and then single colonies  were transferred into selective media 
for YAC DNA isolation using standard procedures.  
 
3.12.2 Sequence tagged site (STS) 
 
STS markers which had been assigned to 2p21-p24 
(http://www.ncbi.nlm.nih.gov/SCIENCE96, http://www.ncbi.nlm.nih.gov/genemap98, 
http://www.ncbi.nlm.nih.gov/genemap99) were used to perform a series of PCR reactions 
with YAC  DNAs. The sequences and annealing temperatures of primers are shown in     
Table 5. 
 
Table 5. Sequence tagged sites (STSs) for YAC , BAC and PAC mapping 
___________________________________________________________________________ 
Name  Primer Sequence (5'->3') Tm ( oC)  Product  
 size (bp) 
___________________________________________________________________________ 
D2S352 D2S352f GCAAAGTCGTTCTCAGGTG 55 205 
 D2S352r CTACAGGGCTTCAGCATCC   
     
D2S367 D2S367f TTCTTTGGTCTAAGGGTCAC 55 148 
 D2S367r AGCTTCTTGTTCACAGGTGT   
     
D2S400 D2S400f AATGTGACAAAGCCCAGTGTTAGC 55 190 
 D2S400r GATAATCTCCCTGAGTATGTGTGCC   
     
D2S1794 D2S1794f TTCTTGCCAGAATGAAGTAAGC 55 124 
 D2S1794r TTGAGGACAAGAGCAGTATAGAGG   
     
D2S1998 D2S1998f TGAAACCCCATTAAGAAGAGATC 55 203 
 D2S1998r GGGAGAACTTTTCAGTTAATATTCC   
___________________________________________________________________________
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D2S2203 D2S2203f AAGTGCTTAGAAGGGTTCCTGAC 55 264 
 D2S2203r ATATGCTCTCTGGTGACTGTAGGTG   
     
D2S2005 D2S2005f ATGAACAGATTTCACTGCTACTCTC 55 226 
 D2S2005r GCCTTTTTCTGAGTTTCTTCTCA   
     
D2S2255 D2S2255f CTCCAGGCTACTTTGAGGATTTT 55 214 
 D2S2255r CCATTTGTTTGCAGATTCTTGTAT   
     
D2S2283 D2S2283f GATCATGGCCCCAATA 55 273 
 D2S2283r GCCCCAGGTAACCACT   
     
D2S2347 D2S2347f TGCCTAAGCCCATGTC 55 272 
 D2S2347r CTGCGTCACTTCACATAGA   
     
D2S2351 D2S2351f TGAACTTTGCAGTGAGAAA 55 241 
 D2S2351r TTTACTGTGTATGTGTGTGTACTCT   
     
D2S3008 D2S3008f CCAGCAGGCAGAGTGAGAATC 63 224-292 
 D2S3008r TGTTTAAAGCACAAGGGCAGT   
     
A004H42 A004H42f AACAAAATTATTACAGGTGG 55 168 
 A004H42r GGTTTATAGTAGTCCATGCTATA   
     
A008N33 A008N33f TAGCAGATACGGTCAAGACTAGT 56 105 
 A008N33r GTGGTTAAATAGTTGACGGATTA   
     
Cda15g09 Cda15g09f GCTTGAAATTCAGGTCCTCTC 56 249 
 Cda15g09r GGGTTATTTGGGGAAGTGTTG   
     
Cda0sd05 Cda0sd05f GCAGTGGCACAATTATAAC 54 155 
 Cda0sd05r AATAAAGTAAGCTCCCGTC   
     
GAAT-
P33068 
GAAT-P33068f TCCTTCATCATGTGATTCCC 55 152 
 GAAT-P33068r TTACCAGTGGCCATTACTGC   
     
N52847 N52847f TAGCAGCTTGGCTAAGAACG 56 110 
 N52847r AGGCCAGTGATTTTGTTCC   
     
SGC32192 SGC32192f TTTTAAAAAGAGACATGGGTCTCA 55 136 
 SGC32192r CTGTAGTGCCACTACTCTGAAAGC   
     
SGC32499 SGC32499f AAATGTCAGCCCTTCACAGC 55 127 
 SGC32499r TACAGTATAGTCAGTGGCAGTTTCC   
     
SGC33436 SGC33436f TCTGCTTTTAAAGATTCTTCATAGC 55 150 
 SGC33436r  AGAGTGGAAATAAGACTGGCTATC   
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SHGC12567 SHGC12567f AGAGAGTCCTCAGCAGAGTCTTC 58    224-245
 SHGC12567r TATTCACCATTTAGGCATAACAGTT   
     
SHGC13568 SHGC13568f TGACCCCCAAGCTTTCTGT 57 139 
 SHGC13568r CCTACAGAAGCAGCAACCGT   
     
stSG1707 stSG1707f TGCACTGCAGTAGTAAGCACG 59 196 
 stSG1707r CCCACTGTACTCAATGCCCT   
     
stSG2515 stSG2515f TGTTGGTGGCAAAGAAAACA 57 186 
 stSG2515r AAGGAAAAGGGTGAAGGGAA   
     
stSG3789 stSG3789f GCAGGTGAAAGCACCTTTTC 55 131 
 stSG3789r CCCAGGGAATTAGCTGATGA   
     
stSG4150 stSG4150f TGCACTGCAGTAGTAAGCACG 58 138 
 stSG4150r GCCCACTGAACCAATCACTT   
     
stSG47880 stSG47880f CTTTGCCATGAATGAGAGCA 55 128 
 stSG47880r  TTGAAGAGGGGATCTTGGTG   
     
stSG15464 stSG15464f CAGCTTGATGAATTTTCACAAA 55 204 
 stSG15464r TTTTGTATGGCCTTAAATCTGG   
     
stSG22421 stSG22421f ACGAGTCTCGACGTGCAAG 56 148 
 stSG22421r TCACTGTTATGGTCCTGTCAGG   
     
stSG29624 stSG29624f CAAAGCTCTGCCCTGTAAGG 56 175 
 stSG29624r ACTGTTGTGGCCTTAATGTCG   
     
stSG30783 stSG30783f TCTACCCTCCAGAAGCTTGTG 55 146 
 stSG30783r TGCTCAACTGCACTGTGAAA   
     
stSG31920 stSG31920f  TAAATCAATAAAGCCAGCCTCT 55 122 
 stSG31920r  AGCAGACATTGCACGGGT   
     
stSG32067 stSG32067f GGTCCGAGTTCAAATTCTGC 55 84 
 stSG32067r CGAGCTCCGTCTCAAAAAAA   
     
stSG44150 stSG44150f TAAAATGTGCTTTCGCTGCA 55 81 
 stSG44150r CGTTATTAAGCTATTGAAGGCC   
     
stSG48207 stSG48207f AGCACGGCAACAAAGAAATT 56 128 
 stSG48207r CGTCTTGAAAGGTGAAAGGTG   
     
stSG51853 stSG51853f AAAAACCCACTTTATGCAACTG 55 135 
 stSG51853r ACCATTTACAGTTCGGTTTTGG   
____________________________________________________________________________
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stSG52124 stSG52124f TAAGCATGGAAGCTACATCAGC 56 189 
 stSG52124r GCCTGGATTTTCCCCTTTAT   
     
stSG62506 stSG62506f ACCTAGTAGGGGCAAGTTTTT  55 140 
 stSG62506r TTCTCTGGTGCTTAAATGATGC   
     
stSG63103 stSG63103f TAAGGGCACCAAAAACCAAC 55 189 
 stSG63103r CCTCATCCCAGCCATGTC   
     
WI9534 WI9534f TTTTATTAACAATTTGTTGGTGGC 55 199 
 WI9534r AAGGAAAAGGGTGAAGGGAA   
WI9668 WI9668f AAACAGTTTAATTCAAGCAATCTGG 55 281 
 WI9668r AGTGTTGGAAAAAAGATTAGGGC   
     
WI11827 WI11827f TTTTTTGCTGTAAAACAAAACACA 55 111 
 WI11827r CATAAAAGTTGGGGAAAGAGACC   
     
     
WI16788 WI16788f TGTCTGGAAATACTTTCCCATT 55 150 
 WI16788r CAGACTCATCAAGTTTCAGCAA   
     
WI16901 WI16901f ACATATGTGCTGTCTACTATGAGCC 55 103 
 WI16901r AAATAGGTACTCCTTGGAATCTGTG   
___________________________________________________________________________ 
 
3.13 BAC and PAC contig construction 
 
To construct  a physical BAC and PAC map, human genomic libraries,RPCI-1, RPCI-6, 
RPCI-11 and human chromosome 2 specific library LL02NP04“AI“ were screened either by 
hybridization or PCR. The sequences and annealing temperatures of the STSs used to screen 
several genomic libraries were shown in the section of YAC contig construction. 
 
3.13 1 High density filter  libraries 
 
The high density filters are ready for prehybridization. A standard hybridization was 
performed as described previously. Several STSs or ESTs that assigned to chromosome 2p21-
24  from the GenBank 98 and 99 Map were chosen as probes for hybridization. The probes 
were  first synthesized by PCR and then labeled with [γ-32P ]ATP at 5’ends. The 5’labeling 
was described in the hybridization section. To reduce the removal of DNA from filters, the 
filters were reused for hybridization in subsequent steps without removing the hybridized 
probes. The new positive hybridizing signals appeared on the autoradiogram after the 
hybridization with a new probe.  If the background was too high, filters were stripped by 
washing at room temperature in 0.2 M NaOH for 30 min, and soaked in 0.1 x SSC/0.1% SDS/ 
0.2 M Tris-HCl pH 7.5 for 15 min. 
The interpretation of  positive signals  was according to the instructions of  German Resource 
Center and UK HGMP Resource center  because different spotting strategies of libraries were 
used. The positive clones were confirmed by PCR and the sizes of the clones were determined 
by PFGE. 
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3.13.2 DNA pool libraries  
 
Two DNA pool libraries, RPCI-6 and RPCI-11, were used for PCR screening. RPCI-6 was a 
PAC library consisted of 36 primary pools. RPCI-11 was a BAC library consisted of 144 
primary pools. DNA primary pools were first screened and the  secondary pools were 
dettermined by the  primary pools screening results. The secondary pools were screened  
further to obtain the positive candidate clones. The DNA primary pool sample (5 µl) was 
diluted with 45 µl sterile water and 1 µl diluted DNA  was used as template for a standard 20 
µl PCR. PCR was performed as described before. The lyophylized DNA secondary pool 
sample needed to be resuspended in 5 µl sterile water and the subsequent procedures of PCR 
screening is the same as described above. 
 
3.14 Genotyping and linkage analysis 
 
DNA was extracted from peripheral blood as described previously and was amplified with 
different STRP markers by standard procedures of PCR. [α32P]-dCTP was incorporated in the 
PCR products during amplification. Amplified DNA was electrophoresed on 6% 
plyacrylamide/7M urea gels, and alleles were scored on the basis of autoradiographs. The 
microsatellite polymorphic markers are listed in Table 6. Two-point LOD scores were 
calculated using  the LINKAGE version 5.1 program package. The following assumptions   
were made: a gene frequency of 10-5 for autosomal dominant SPG; equal allele frequencies for 
each marker; equal recombination rates in males and females and 90% as  the penetrance rate. 
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Table 6. STRPs markers for linkage analysis at SPG 3,4, 6 loci. 
____________________________________________________________________________ 
Name  Primer Sequence Tm(oC)   Product  
  size(bp) 
____________________________________________________________________________ 
SPG3_____   
D14S63 D14S63A GGCCAGGTTTCAATCAGTTT 55 208 
 D14S63B GCCAGAGAGCCACACTGTAT   
D14S66 D14S66A GGCAACAGACTTGACCAATC 55 185 
 D14S66B CGTTCAGTAAGCAGAGAGCA   
D14S69 D14S69A AAAGCCACACTGCTAGTCAC 55 204 
 D14S69B TTCAGATGCCAATTAAGGGA   
D14S75 D14S75A TGTCCCCAGGTGTTA 55 185 
 D14S75B CCAAGTGGCCTTGCC   
D14S79 D14S79A AGGTTGATAGACCATGGAGACA 55 82 
 D14S79B TTTTATTGTTATGTGGCTTTCA   
D14S266 D14S266A ACAAGCCCCATATATTCATG 55 135 
 D14S266B AATAGACTTCCAAATCTTCAGATA   
D14S269 D14S269A CACATGGCATTACCAC 55 221 
 D14S269B GCAACATGCTTGACAGG   
SPG4_____    
D2S146 D2S146A TCATCCTTACTCTAAGCAAAGATCC 55 189 
 D2S146B CACCACATTCAAATGCCTCC   
D2S170 D2S170A TTGCTCAATAATGTCAGGTG 55 216 
 D2S170B CGCATGAGAGGCGTCT   
D2S352 D2S352A GCAAAGTCGTTCTCAGGTG 55 205 
 D2S352B CTACAGGGCTTCAGCATCC   
D2S367 D2S367A TTCTTTGGTCTAAGGGTCAC 55 148 
 D2S367B AGCTTCTTGTTCACAGGTGT   
D2S400 D2S400A AATGTGACAAAGCCCAGTGTTAGC 55 190 
 D2S400B GATAATCTCCCTGAGTATGTGTGCC   
SPG6_____    
D15S122 D15S122A GATAATCATGCCCCCCA 55 146 
 D15S122B CCCAGTATCTGGCACGTAG   
D15S128 D15S128A GCTGTGTGTAAGTGTGTTTTATATC 55 206 
 D15S128B GCAAGCCAGTGGAGAG   
D15S156 D15S156A CAGCCACCGCATTCTA 55 229 
 D15S156B CAACACCATTTATTGAAGAGAC   
D15S165 D15S165A GTTTACGCCTCATGGATTTA 55 208 
 D15S165B GGGCACACAGTCCCAA   
_____________________________________________________________________________
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3.15 WWW. web sites 
 
Organization/Database                                                    Address 
The National Center for Biotechnology Information      http://www.ncbi.nlm.nih.gov/ 
     Medline                                                                      http://www.ncbi.nlm.nih.gov/PubMed/ 
     Online Mendelian Inheritance in Man                       http://www.ncbi.nlm.nih.gov/Omim/ 
     (Human Genes and Genetic Disorders) 
 
Cooperative Human Linkage Center                              http://lpg.nci.nih.gov/CHLC/ 
(Human Genome Map) 
 
Whitehead Institute (Physical Mapping)                         http://www-genome.wi.mit.edu/ 
 
Online Linkage Analysis Software                                 http://linkage.rockefeller.edu/ 
 
Standford Human Genome Center                                 http://www-shgc.stanford.edu/ 
(Radiation Hybrids Mapping) 
 
European Bioinformatics Institute                                  http://www.ebi.ac.uk/ 
(Sequence Database) 
 
Radiation Hybrids database                                            http://www.ebi.ac.uk/RHdb/ 
 
Human Gene Mutation Database                                    http://www.archive.uwcm.ac.uk/ 
 
UK Human Genome Mapping Project                            http://www.hgmp.mrc.ac.uk/ 
Resource Cernter (HGMP) 
 
Sanger Institute (Human Genome Sequences)                http://www.sanger.ac.uk 
 
Genome database                                                            http://www.gdb.org/ 
 
German Resource Center                                                http://www.rzpd.de/ 
(German Human Genome Project Funded) 
 
CEPH (YAC Mapping)                                                   http://www.cephb.fr/ 
 
Genethon (SSLP Maps)                                                  http://www.genethon.fr/ 
 
Genoscope                                                                      http://www.genoscope.cns.fr/ 
(Human Chromosome 2p21-p24 Sequences) 
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4 Results 
 
4.1 Clinical Data 
 
The pedigree of the large family with pure spastic paraplegia is studied and shown in Figure 1. 
This family consists of 66 living members and the blood samples were collected from           
42 participating members. HSP was diagnosed in 5 living members. One additional individual     
(IV:23) had minor symptoms (dorsal reflexes) and was thus diagnosed as presymptomatic. 
Ages of disease onset in this family vary from 12 years (patient IV:19) to 51 years (patient 
III:1). Brief case histories are presented below. 
 
Patient III:1 
This 60 year old man allegedly had multiple sclerosis since he was 51. Examination showed 
that reflexes were stronger on the left than on the right. He had mild paraparesis of the legs 
and a pathological right Babinski reflex, and positive Trömmner signs. There was no sensory 
disturbance, and no impaired bladder function. Eyes were not involved. 
 
Patient III:12 
This 56 year old man had frequently fallen in childhood and acute symptoms began when he 
was 25. Examination showed paraparesis of the lower limbs and bilateral Babinski signs. He 
was able to walk without a stick.  
 
Patient III:14 
This 57 year old man began to show the symptoms slowly since he was 46. Examination 
showed paraparesis of the lower limbs and bilateral Babinski signs. Function of his upper 
limbs was not disturbed and he was able to walk without a stick. 
 
Patient IV:19 
This 41 year old woman had gait disturbance since she was 12 years old. Examination showed 
increased muscular reflexes, spasticity in lower limbs and bilateral Babinski signs. She was 
able to walk without a stick. 
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Patient IV:23 
This 25 year old woman had Trömmner but no Babinski signs when she was diagnosed as 
presymptomatic. 
 
The patients of this family showed the common phenotype of spastic paraparesis and various 
ages of onset. Individuals of both sexes were affected. In addition, male to male transmission 
was observed (II:3 to III12 and III14). These results are consistent with the autosomal 
dominant inheritance of SPG in this family. Linkage analysis was performed with markers at 
the three loci (SPG3, SPG4, SPG6) known at the time 1997 in AD-HSP. 
 
4.2 Genotype and linkage results 
 
4.2.1 Two points lod score of the SPG4 family 
 
Three sets of STRPs markers were chosen for linkage analysis in the large HSP family. The 
markers had been previously described to be linked to three SPG loci (SPG3, 4, 6). D14S75, 
D14S79, D14S69, D14S266, D14S269, D14S66 and D14S63 (SPG3). D2S170, D2S146, 
D2S400, D2S352, and D2S367 (SPG4). D15S128, D15S122, D15S156 and D15S165 (SPG6). 
Primer sequences of the polymorphic microsatellite markers  are given in Table 6. Two-point 
lod scores were calculated for markers on chromosome 2p, 14q and 15q. A maximum lod 
score of 3.63 at θ =0 was obtained with locus D2S367 in the large AD-HSP family. Two 
chromosome 2p markers D2S352 and D2S367 show significant evidence of linkage (lod 
scores >3). Two-point lod scores are summarized in Table 7 and there is no evidence of 
linkage to chromosome 14q or 15q in (Z<-2) in this family. The haplotype analysis and the 
results of two point lod scores indicate that the disease locus in this AD-HSP family is linked 
to chromosome 2p (SPG4). 
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Table 7. Two -point lod scores of the SPG famliy vs chromosome 14q, 15q, 2p markers 
 
SPG locus Microsatellite  Lod scores Z at recombination fraction (θ)        Zmax    θmax
 0,00 0,01 0,05 0,10 0,2 0,3 0,4   
__________________________________________________________________
SPG3 D14S75 -9,52 -3,92 -2,12 -1,26 -0,47 -0,13 -0,01  0,00 0,50
 D14S79 -12,94 -5,55 -3,04 -1,78 -0,61 -0,13 0,03  0,03 0,40
 D14S69 1,08 1,09 1,05 0,96 0,68 0,36 0,09  1,09 0,01
 D14S266 -7,50 -1,91 -0,96 -0,51 -0,15 -0,04 -0,01  0,00 0,50
 D14S269 -7,50 -1,47 -0,72 -0,51 -0,15 -0,04 -0,01  0,00 0,50
 D14S66 -1,01 -0,87 -0,56 -0,34 -0,13 -0,04 -0,01  0,00 0,50
 D14S63 -16,69 -6,61 -3,79 -2,43 -1,09 -0,42 -0,09  0,00 0,50
     
SPG6 D15S128 -0,53 -0,49 -0,36 -0,28 -0,18 -0,09 -0,02  0,00 0,50
 D15S122 -4,82 -3,40 -1,83 -0,98 -0,25 -0,02 0,00  0,00 0,50
 D15S156 -9,80 -2,90 -1,34 -0,65 -0,08 0,10 0,10  0,10 0,30
 D15S165 -9,45 -4,49 -2,36 -1,45 -0,62 -0,22 -0,04  0,00 0,50
     
SPG4 D2S170      − ∞ -4,55 -1,88 -0,88 -0,14 0,02 0,00  0,03 0,32
 D2S146 0,11 0,10 0,08 0,07 0,04 0,01 0,00  0,11 0,00
 D2S400 1,73 1,69 1,54 1,34 0,93 0,52 0,15  1,73 0,00
 D2S352 3,35 3,39 3,34 3,09 2,36 1,47 0,55   3,39 0,01
 D2S367 3,63 3,61 3,47 3,19 2,46 1,56 0,61   3,63 0,00
_________________________________________________________________ 
The maximum Lod scores at loci D2S352 and D2S367 were indicated in boldface. 
     
 
 
4.2.2 Haplotype of the SPG4 family 
 
The core haplotype includes the region flanked by D2S146 and D2S367. The haplotype was 
constructed at 5 loci surrounding SPG4 and is shown in Figure 1. The order of markers of 
haplotypes is consistent with the previously reported physical map of the region. A common 
haplotype was found in all 5 affected family members. Individual IV:23, who had very mild 
symptoms, has the same core haploptype and was considered presymptomatic by clinical 
criteria. A recombination event was found in IV:22. This reduces the critical  interval of 3 cM 
between D2S352 and  D2S367, since the recombination occurred at locus D2S352.  This 
recombination  was also found by Dub∈ et al.47 and Scott et al.35. Individuals IV:1 and IV:3 
may carry the disease alleles at loci D2S352 and D2S367 from their affected father III:1. If 
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they were carriers, they can not be confidently identified as non-penetrance, though the 
neurological examination showed asymptomatic at their ages of 30 and 26, respectively. 
 
In section 4.2, two points lod scores and haplotype reveal that the disease locus of the large 
AD-HSP family is linked to chromosome 2p (SPG4). The lod score > 3 corresponds to the 
conventional p<0.05 threshold of statistical significance for accepting likage. Linkage can be 
rejected if the lod score < -2. The lod scores between –2 and +3 are inconclusive. 
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4.3 YAC Contig Mapping  
 
To facilitate positional cloning of the SPG4 gene, a contiguous YAC map which covered the 
SPG4 critical region was established. 
 
4.3.1 YAC Contig Spanning the SPG4 Critical Region between D2S400 and D2S367 
 
The human DNA insert of 26 YACs that had been assigned to 2p21-24 were fine mapped in 
order to determine whether the YACs are located within the SPG4 candidate region. The 
YACs were  examined by PCR for presence of the sequences tagged sites (STSs) D2S400, 
D2S2255, stSG4150, SHGC12567, stSG1707, D2S352, D2S2283, D2S2203, D2S3008, 
D2S2351, WI9534, SGC32499, SGC32192, WI9668, WI11827, WI16901, SHGC13568, 
A004H42, stSG3789, WI16788, GAAT-P33068, D2S1794, D2S2347, D2S2005, WI9249, 
D2S1998, SGC33436, D2S367 which were previously located in the candidate region 
(Hudson et al,48). The sequences of STSs primers are listed in Table 6. A total of 24 YACs 
were positive for one or more STSs, While 15 YACs contain multiple STRs. Compared to the 
previously described contig ( De Jonghe et al.49), ten additional YACs (715F10, 737D8, 
774D8, 785G12, 823C6, 851F4, 884D5, 894E4, 923E10, 947E2) and six STRs (D2S2255, 
D2S2283, D2S2203, D2S3008, D2S2351, D2S2347) were newly assigned to the YAC contig 
(see Figure  2).  
 
4.3.2 13 ESTs were newly assigned to the SPG4 critical region 
 
A total of 13 ESTs were mapped to the YAC contig out of 27 ESTs which had been assigned 
to 2p21-p24 (http://www.ncbi.nlm.nih.gov/SCIENCE96/). Only one of those ESTs, 
SHGC12567, was found to be part of a known gene, i.e. human xanthine dehydrogenase 
(100% homology). The remaining ESTs did not have striking homologies with known genes. 
The YACs spanned the complete candidate region between D2S400 and D2S367 (Lau et al50). 
The order of the STRs are consistent with the physical map of Hudson et al48. The density of 
clone coverage is variable along the YAC contig, and ranges from 2 clones at WI9249 to a 
maximum of 10 clones at WI9534 and D2S2351 (see Figure 2). 
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4.3.3 The size of the SPG4 critical region 
 
The sizes of YACs of the contig were determined by PFGE  and  are  listed in Table 8. The 
physical size of ∼3.6 Mb was estimated for the SPG4 critical region on the basis of 2 YACs: 
937D3 and 923E10. This result  is very similar to another estimation reported by Hazan et 
al.37, who constructed a 3.5 Mb YAC contig between D2S367 and D2S400. The 
overestimation of the physical size of SPG4 locus was due to the chimerism of YACs in the 
previous study49. Supposed that SPG4 critical region is 3.6 Mb, the average physical distance 
of every two STSs in the YAC contig is 124 kb 
 
Table 8. YAC sizes  
__________________________________ 
YAC         Size (kb)  
__________________________________ 
701D7 750  
715F10 1200  
718B10 1250  
737D8 1200  
738A9 1050  
751C9 1800  
774D8 1200  
785G12 800  
802A5 400;1800  
823C6 1600  
851F4 1600  
884D5 1050  
894E4 1000  
895C12 1500  
912A7 1000  
923E10 1800  
931E1 1800  
931G7 1550  
934C11 1600  
937D3 1800  
947E2 650  
958D2 1200  
965E8 1600  
___________________________________ 
Note: Different sizes of the same YACs are probably 
due to in vivo truncation of an ancestral YAC 
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Of 19 STSs tested on the 17 YAC clones, 40 YAC/STS hits reported in contig WC2.3 
established by the Whitehead Institute were confirmed and 54 new hits were assigned    (see 
Table 9). One false-positive hit, YAC 774D8 at locus D2S400 was found in CEPH database 
and one false-negative, YAC 923E10 at locus D2S2351, was found in Hazan’s publication37.  
This result is consistent with the estimation of Hudson et al.48 in which the false positive rate 
is at the maximum 5% in definite addresses and the 20% average false negative rate is 
suggested.  The false positive and  negative signals may result from the recombinations and 
deletions during the YAC regrowth or technical failures. 
 
Table 9.Newly assigned STSs content of YACs compared with the Whitehead Institute/MIT  
            contig WC 2.3 database     
____________________________________________________________________________ 
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____________________________________________________________________________ 
D2S400 v v v               
D2S2255 + + +               
D2S352  +  v v +            
D2S2283  v  v v v            
D2S2203  +  + + + +           
D2S3008  +  + + + +           
D2S2351  v  v +  + + v v + v  +    
WI9534  v  v   v v v v v +  v    
WI9668       v v v v + v v +    
WI11827       + + + + + + + +    
WI16901       + + + + + + + +    
WI16788         + +    + + +  
GAAT-P33068        v     + + v  
D2S1794         v     v v v  
D2S2347         +     + + +  
D2S2005         +     + v v  
WI9249              v +   
D2S1998              v v  v 
D2S367                 + 
____________________________________________________________________________ 
Note:YACs are on the top, and STSs are on the left .''+'', newly assigned STSs; ''v'' , verified 
hits. 
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4.4 Search for CAG /CTG Repeats in the SPG4 Critical Region 2p21-p24 
Several SPG4-linked families have exhibited  anticipation which is a hallmark of trinucleotide 
repeat expansion diseases. Nielsen et al.51 reported (CAG)n trinucleotide repeats expanded in 
their SPG4-linked patients by  the RED ( repeats expansion detection) method52. Therefore, to 
clone the CAG/CTG repeat fragments in SPG4 critical region was once the strategy to explore 
the disease mechanism. 
 
4.4.1 Construction of Cosmid Libraries within SPG4 Critical Region  
 
Cosmid libraries were constructed from 4 YACs (738A9, 937D3, 923E10, and 895C12) 
spanning the SPG4 candidate region. These libraries are composed of between  2000 and 2500  
clones and were screened with human genomic DNA. Subsequently, positive clones were 
hybridized with a (CAG)10 oligonucleotide to find those fragments which contain CAG/CTG 
repeats. The  outline of the cloning procedures is shown in Figure 3.  
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4.4.2 Isolation of Six CAG/CTG Repeat Containing Fragments  
A total of 6 sets human CAG/CTG repeats containing  cosmids were isolated from 3 YACs 
(738A9, 937D3 and 923E10). YAC 895C12 does not contain CAG/CTG repeats. The clones 
positive for human DNA and CAG repeats were cleaved with EcoR I and Hind III (Figure 4) 
and subcloned into plasmid  pBluescript II KS (+). The subclones were sequenced by MWG 
CL4200 autosequencer.  
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4.4.3 Identification of One New STRP for Indirect Diagnosis 
 
One  (CAG)3 containing fragment, denoted clone A8, was derived from YAC 738A9. 
Sequence analysis shows that it also includes  a (GAAA)n(GGAA)n tetranucleotide repeat. 
The tetranucleotide repeats were amplified using the flanking primers 5’-
CCAGCAGGCAGAGTGAGAATC-3’ (forward) and 5’-TGTTTAAAGCACAAGGGCAGT-
3’ (reverse). PCR conditions were 30 cycles at 94oC for 30 sec, 63oC for 60 sec, and at 70oC 
for 15 sec. The reaction was preceded by 5 min denaturation at 94oC and followed by a final 
extension at 70oC  for 5 min .The sequence  was found to be highly polymorphic and a total of 
28 alleles ranging in size from 224 to 292 bp were identified in 50 Caucasian DNA samples    
(see Table 10). 
The locus, designated D2S3008, was flanked by loci D2S352 and D2S2283 distally and 
D2S2351 proximally (see Figure 2. Lau et al.50). The marker has a heterozygosity of 0.81 and 
a PIC (polymorphism information content) value of 0.78. The heterozygosity (H) which refers 
the degree of polymorphism is defined by H= 1 -Σ p2i, where pi is the population frequency of 
the ith allele, and H is the probability that a random individual is heterozygous for any two 
alleles at a gene locus with  allele frequencies, pi. The PIC value is defined as the probability 
that the marker genotype of a given offspring will allow deduction of which of the two marker 
alleles of the affected parent it had received.  PIC is calculated as PIC = 1-Σ p2i -Σn-1i=1 Σnj= 
i+12pi2pj2 , where pi is the population frequency of the ith allele.  
 
 
 
 
 
 
 
 
 
 
 
 
 
__________________________________________Result_______________________________________ 
 
60
 
 
Table 10. Allele sizes at locus D2S3008 in the Caucasian population; 100 chromosomes 
                 2 were studied. PIC: 0.78, heterozygosity: 0.81 
_______________________________________________________________________
            Allele Allele sizes (bp) Allele frequency 
_______________________________________________________________________
1  224 1  
2  229 1  
3  230 1  
4  232 3  
5  234 3  
6  236 6  
7  238 3  
8  240 4  
9  243 7  
10  245 5  
11  247 5  
12  249 6  
13  250 5  
14  252 3  
15  254 5  
16  256 4  
17  258 5  
18  260 4  
19  262 3  
20  264 4  
21  268 4  
22  270 6  
23  273 3  
24  275 1  
25  278 2  
26  280 4  
27  283 1  
28  292 1  
_______________________________________________________________ 
 
 
In addition, a 254 bp allele at D2S3008 segregated in the patients of the SPG4 family (see 
Figure 5). This highly polymorphic STRP can be used as indirect diagnosis of SPG4. 
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4.4.4 Development of Five New STS and Anchoring in  the SPG4 Critical Region. 
 
One  CAG triplet rich fragment, clone D1, was isolated from YAC 937D3 and this clone  
contains a sporadic single CAG unit. Two (CAG)2 repeats fragments denoted clones D5, D6 
were also isolated from YAC 937D3. Two  (CTG)6 -containing fragments were isolated (one 
denoted clone D4 from YAC 937D3, and one denoted clone E11 from YAC 923E10).  
A BLASTN similarity search (Altschul et al.53) with the sequence of each CAG/CTG 
containing fragments  against GenBank division’s dbEST and dbSTS, showed identifies for 
sequences of clones A8, D1, D4, D5, D6 and E11  (see Table 11). Clone A8  matched to BAC 
41M14 of human CITB_978_SKB library with 96% sequence identity. Clone D1  showed 
98% identity  with human BAC RP11-62F14 (accession number AC009301). Clone D4 
showed 97% identity with BAC RP11-62F14. Clone D5 showed 98% identity to the human 
chromosome 2 working draft sequence located in the cluster Hs2_5351. Clone D6 was 99% 
identical to human BAC RP11-62F14. Clone E11 was  99% identical to the human 
chromosome 2 working draft sequence located in the cluster Hs2_5351. These six clones 
which contain CAG repeats did not have striking homologies with known genes.  
 
 
Table 11. Summary of the both human DNA and (CAG)n positive fragments from YACs 
               738A9, 923E10, and 937D3 within SPG4 locus 
________________________________________________________________________________________
YAC Clone Fragment length (kb) CAG/CTG repeat BLASTN analysis 
   units 
________________________________________________________________________________________
738A9 A8 3.5 3 human BAC clone 41M14 of 
    CITB_978_SKB library 
923E10 E11 4.2 6 human chromosome 2 working draft 
    cluster Hs2_5351 
937D3 D1 2.3 1 human BAC cloneRP11-62F14 
 D4 2.3 6 human BAC cloneRP11-62F14 
 D5 1.1 2 human chromosome 2 working draft 
    cluster Hs2_5351 
 D6 2.1 2 human BAC cloneRP11-62F14 
________________________________________________________________________________________
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Furthermore, five new STSs were developed on the basis of  clones D1, D5, D6, D4, E11. 
They are denoted by cag1c1p, cag2c5p, cag2c6p, ctg6c4, ctg6c11 and were anchored in the 
SPG4 candidate region (Figure 8). The new STSs and D2S3008 are listed in Table 12. 
 
 
Table 12. Newly developed STSs in this study 
__________________________________________________________________________________
Name GenBank 
Accession  
 Primer Sequence Product size 
 number           (bp) 
__________________________________________________________________________________
cag1c1p G67940   cag1c1p.a GCCCCAGAAACAGCCAAATAA 385 
    cag1c1p.b CGCCAGCAACGCCAGTC  
      
cag2c5p G67941   cag2c5p.a TGGGGAGTGGTTTAGTAGCAGAAG 250 
    cag2c5p.b AGCGACATACATACAAGGGAAAAA  
      
cag2c6p G67942   cag2c6p.a AACAGCCCCCTATCACATTCCAGA 332 
    cag2c6p.b GGCACATCCCAGCATTTAGCAGTA  
      
ctg6c4 G67794   ctg6c4.a TCTACACATCCCATTTGCCTTTCT 256 
    ctg6c4.b TAGCCTCTCCGAGCCTTGGTT  
      
ctg6c11 G67795   ctg6c11.a GGGCGCGAGACACAGGATTC 422 
    ctg6c11.b TGACAAGTGGTGCGATTTATT  
      
D2S3008 AF095704   D2S3008.a CCAGCAGGCAGAGTGAGAATC 224-292 
   D2S3008.b TGTTTAAAGCACAAGGGCAGT 
__________________________________________________________________________________
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4.4.5 Analysis of the CAG/CTG Repeats in SPG4 Patients 
 
Since the CAG/CTG repeats involved in neuron degenerative diseases are usually more than 3 
repeat units in coding region, we used two cloned sequences which included (CTG)6 to 
generate PCR primers for repeats expansion analysis. The alleles were amplified with PCR in 
which [α32P]-dCTP was incorporated into the synthesized PCR fragments. The radioactive 
labeled products were electrophoresed on  denaturing polyacrylamide gels. The controls and 
patients have 256bp and 422bp homozygous alleles at loci ctg6c4 and ctg6c11, respectively. 
None of (CTG)6 repeats are expanded in affected members of the SPG4 linked family. In 
addition, no differences were observed in the number of repeat units between human and 
YAC DNA (see Figure 6 and 7). 
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4.5 BAC/PAC Contig Mapping 
 
The failure to identify an expanded CAG/CTG repeat within the SPG4 candidate region may 
be caused by a deletion in one of the YACs or high rates of chimerism of YACs used to 
construct the cosmid libraries. Therefore, we started to construct a BAC/PAC contig.  
 
 
4.5.1 Updating the STSs to the Contig 
 
To update ESTs and also increase the density of  ESTs in the SPG4 critical region, we 
searched the databases Gene Map 98 and 99 during the experiment (see Table 13). These 
selected ESTs from databases were first tested with the YACs in the contig. Twenty ESTs 
were newly assigned to the SPG4 critical region. Together with the previously mapped ESTs 
which were selected from  Gene Map 96 in the YAC contig, a total of 36 ESTs and 12 STRs 
were integrated in the SPG4 candidate region between D2S367 and D2S400. Primer  
sequences of ESTs and STRs are shown in Table 6. In addition to SHGC12567 which had 
100% homology with human xanthine dehydrogenase54,  three ESTs were found to be parts of 
known genes. N52847 was identical with latent transforming growth factor beta binding 
protein 1 (LTBP1)55 and  stSG 4150 and stSG1707 were a part of  human EH-domain 
containing protein 3 (EHD3)56. 
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Table 13.YAC contig integrated with ESTs  from Gene Map 98 and 99 
YAC  EST 
st
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8N
33
 
N
52
84
7 
    
          
718B10 +                   
737D8  + + +  + + + + + + +    + + +  
738A9  + +             +  +  
751C9  + + +  + + +            
785G12       + + + + + +     +   
802A5             + + +    + 
823C6  + + +  + + + +       + + +  
851F4  + + +  + + + + + + +    +  +  
923E10  + +   + + + + + + + + + + + + + + 
931E1  + + +  + + + + + + +  + + + + +  
931G7  + + +  + + + +  + + +   + + +  
934C11             + +      
937D3 + + +                 
947E2   + +  + + + + + +     + + +  
965E8 +         
 
Note: YACs are on the left and Ests are on the top. "+" , PCR positive. 
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4.5.2 Assembly of Several BACs and PACs in SPG4 Critical Region 
 
The BAC library RPCI-11, the two PAC librairies RPCI-1  and RPCI-6, and the  chromosome 
2-specific PAC library LL02NP04’AI’ were screened by hybridization with PCR products for 
filter libraries or directly screened by PCR using DNA pool libraries against the STSs 
localized in the SPG4 critical region between D2S400 and D2S367.  A total of 52 BAC/ PAC 
clones  which comprised 19 BACs  and 33 PACs  were assigned to the SPG4 candidate region 
(see Figure 8). 
 
 
 
4.5.3 SPAST is located in the BAC bG11100  
 
While this contig construction was going on, Hazan et al.36,37 published 1.5 Mb sequences in 
the SPG4 critical region and identified five mutations of SPG4 patients in a novel gene named 
SPAST. Since  Hazan found that SPAST is very close to the locus D2S2351, the  adjacent 
BACs and PACs in the contig were screened for SPAST. Several exons of SPAST (exon 1, 2, 
11, 12, 16, 17) were tested against those adjacent BACs and PACs (59b24, 69d15, 122b3, 
N15143, bA16130, bK08201, bP12129, bP13129, bB07176, bC11100, bG11100) by PCR. 
The PCR primers are shown in Table 4. The result reveals that SPAST is located in BAC clone 
bG11100 (see Figure 8) 
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4.5.4 Sizes of BACs and PACs 
 
Sizes of several PACs and BACs were determined by PFGE (see Table 14). The contig built 
in this dissertation is about  2.2 Mb,  of which 1.2 Mb is located in SPG4 minimum critical 
region. This estimation takes into account the sizes of these clones P17234, A0827,105d11, 
bK13144, bP13129, 59b24, bG11100, B043, G1183, C1011, P2046, H19197, J17106, 
bP09265, 018191, 126m18, bA2313. The contig covers 80% of SPG4 minimum region, 
however there is still 9 gaps in the whole  contig (see Figure 8).  
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Table 14. PACs and BACs sizes   
____________________________________________________________________ 
Clone  Size(kb) Clone  Size(kb) 
____________________________________________________________________ 
PACs:  BACs:   
RPCI1-59b24 90 RPCIB753A2313 150 
RPCI1-61d7 20;90 RPCIB753A16130 100 
RPCI1-69d15 90 RPCIB753A21163 130 
RPCI1-105d11 150 RPCIB753B07176 120 
RPCI1-113e2 120 RPCIB753C11100 120 
RPCI1-113f2 110 RPCIB753D16113 150 
RPCI1-118c4 150 RPCIB753E16113 140 
RPCI1-122b3 120 RPCIB753G0743 100 
RPCI1-126m18 170 RPCIB753G11100 120 
RPCI1-151k12 150 RPCIB753K13144 145 
LLNLP708B043 150 RPCIB753K08201 100 
LLNLP708C1011 90 RPCIB753L0314 160 
LLNLP708E157 40;50 RPCIB753P09265 170 
LLNLP708I213 30;70 RPCIB753P12129 100 
LLNLP708J213 30;70 RPCIB753P13129 100 
LLNLP708K165 40;50   
LLNLP709A0827 50;70   
LLNLP709A14127 150   
LLNLP709A23175 90   
LLNLP709B0240 30   
LLNLP709E13129 100   
LLNLP709F0733 120   
LLNLP709G1138 50;60   
LLNLP709G04178 120   
LLNLP709H19197 150   
LLNLP709J2428 120   
LLNLP709J17106 170   
LLNLP709M1711 110   
LLNLP709N15143 100   
LLNLP709O0557 120   
LLNLP709O18191 170   
LLNLP709P2046 90   
LLNLP709P17234 120   
____________________________________________________________________ 
Different sizes of the same PACs are probably due to an internal Not I restriction site of insert 
DNA 
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4.6 Mutation detection of SPG4 patients 
 
The 17 exons of SPAST  were amplified by PCR from genomic DNA of patients and controls. 
The primers used for PCR amplification and sequencing are shown in Table 4. Sequence  
analysis was done with terminators sequencing method using P33-dd NTP. 
 
4.6.1 Identification of A Novel Mutation 1206-1209del CCTT  
 
One novel mutation 1206-1209delCCTT (Pro361Leu and Ser362Stop) was identified in exon 
7 of SPAST gene (see Figure 9). The same mutation was not observed in ten independent 
controls or unaffected members of this family. The mutation resulted in a truncated spastin 
which lacks three functional domains, the Walker motif A, Walker motif B, and the AAA 
minimal consensus sequence. The Walker motif A located at amino acid positions 382-389, 
also called p-loop, corresponds to the ATPase binding domain. The Walker motif B and the 
AAA minimal consensus are located in amino acids 437-442 and 480-498, respectively.  
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4.6.2 Identification of An Intronic polymorphism 1298+17A>C  
 
A polymorphism 1298+17A>C was found in intron 8 of SPAST in one SPG affected patient 
(see Figure 10 ). A total of 100 unrelated individuals were tested against this polymorphism. 
The same polymorphism was coincidentally found in one unrelated control (Figure 10,11). 
This polymorphism was amplified using the flanking primers 5’-
ACCTGGGAATGGGAAGACA-3’(forward) and 5’-AATAGACTCAAGGACAAGAT-
AAAG-3’ (reverse). The PCR conditions were 30 cycles at 94°C for 30 sec, 60°C for 60 sec, 
and at 70°C for 15 sec. The reaction was preceded by 5 min denaturation at 94°C and 
followed by a final extension at 70°C for 5 min. 
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The  SPG4 family was screened in all 17 exons, intron 6, 10, 11, the 5’ and 3’ untranslated 
region. The sequences of PCR primers for SPAST amplification and sequencing are listed in  
Table 4. However, there was no mutation found in these regions. Furthermore, RT-PCR  was 
performed for this SPG4-linked family. One patient´s blood sample was prepared for RNA 
isolation  and subsequent cDNA synthesis. Five pairs of PCR primers were adapted from 
Genoscope database to amplify four overlapping PCR products  in SPAST cDNA. These 
primers are shown in Table 3. The first PCR fragment flanked by SPA-Db/Dm and SPA-
Dc/Dn can not be amplified in our samples. This may be due to degradation of RNA or a high 
GC content in exon 1. The other three PCR overlapping fragments were amplified. However, 
an aberrant  PCR product  amplified by SPA-Ba/Bm was detected in this patient and two 
normal lab-control samples.  Exon 8 is skipped  in this aberrant PCR product (see Figure 12 
and 13). This aberrant product may result from the degradation of RNA which was isolated 
from the post delivered blood sample. In the control samples, the same splicing artifact was 
observed after blood samples were placed for 10 hr at room temperature 
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5 Discussion 
5.1 Discovering SPAST  
In this dissertation, linkage analysis in a large ADHSP family revealed that the disease locus is 
linked to SPG4 in this family. In order to explore the SPG4 locus, a YAC contig covering the 
SPG4 candidate region was constructed as the first step of positional cloning of SPG4.  
 
Positional cloning57 allows the detection of disease genes without knowledge of the altered 
gene products. This method is thus superior to traditional cloning approaches which rely on 
known gene products and use this information (i.e. the amino acid sequence) to isolate the 
gene. Positional cloning was introduced to the identification of human disease genes in the  
early 1980s. Four major steps are involved in positional cloning: (1) chromosomal mapping of  
the disease gene by either linkage analysis or analysis of chromosomal rearrangements. (2) 
construction of a physical map of the region containing the disease gene (3) identification of  
the gene (4) determination of gene function.  
 
Linkage was discovered by Morgan (1911) in drosophila58 and was also found to be 
applicable to humans. The first demonstration of linkage in humans was done by Bell and 
Haldane59, who showed that in some families, hemophilia and color blindness tended to be 
inherited together rather than segregating independently. Linkage is defined as the tendency 
for two genes close together on the same chromosome to be transmitted together through 
meiosis. The recombinant frequency between loci on the same chromosome is roughly 
proportional to their distance apart, and that allows the use of recombinant fraction to define 
chromosomal mapping units. The mathematical relationship between recombination fraction 
and genetic distance is defined by the mapping function. Assuming that recombination occurs 
at random along the bivalent and no influence on one another, the appropriate mapping 
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function is described as Haldane’s function60: ϖ = -1/2ln(1-2θ), where ϖ is the map distance 
and θ the recombinaion fraction. Nowadays, the human genome has been saturated with 
polymorphic genetic markers that it is often advisable to estimate linkage analysis; the 
LINKAGE package61,62 has proven to be very useful. It is usually convenient to work not with 
the likelihood ratio but with its logarithm, the so-called lod (logarithm of odds) score Z(θ)= 
log L(θ)=log[L(θ)/L(1/2)]; where θ is the recombination fraction, and by construction 
Z(1/2)=0. Two point lod scores are usually estimated at θ values 0, 0.01, 0.05, 0.1, 0.2 , 
0.3,and 0.4. Generally, lod scores are calculated at fixed values of θ between 0 and 0.5, often 
in steps of 0.05. A lod score > 3 indicates a significant linkage (p<0.05) and  a lod score < -2 
indicates an exclusion of linkage. Another approach to the mapping of disease genes is 
cytogenetic studies on chromosomal abnormality (translocations, inversions, deletions, 
duplication, or other rearrangement) can assist positional cloning of human disease genes63. In 
particular, chromosomal abnormalities have been used to map most of the tumor suppresser 
genes or other cancer-related genes. For example, the cytogenetic detection of deletion on 
13q13.1-q14.5 facilitated the identification of the RB gene in Retinoblastoma64.  
 
There are two types of maps: genetic maps and physical maps. Genetic mapping relies on the 
genetic methods including linkage analysis of pedigree in case of human or, cross-breeding 
tests in experimental animals. Genetic maps are defined by mapping functions of 
recombination fractions. Two loci which show 1% recombination are defined as being 1 cM 
apart on a genetic map. Physical maps refer to a real distance in units of nucleotides. Different 
types of physical maps such as radiation hybrid maps65, restriction maps66, maps of 
overlapping, bacteriophage P167, cosmid68, BAC69, PAC70, YAC71 inserts of human genome 
have been constructed. The clone contig maps are widely used as the sources  for DNA 
sequencing in various Genome projects. The first generation physical contig map72 of human 
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genome is so-called YAC contig. Although the large inserts of YAC are very useful in 
chromosome mapping, many YAC inserts are chimeric or have internal deletions. Therefore, 
second generation clone contig maps which rely on BACs and PACs are developed. The 
inserts of BACs and PACs (70-230 kb) are much smaller than YAC inserts (in units of Mb), 
however, BACs and PACs are without the disadvantages of deletions or insertions. Currently, 
BACs and PACs contigs are the primary templates for human genome sequencing. To 
establish a clone contig, for example, YAC, BAC, or PAC contigs, the most common 
approach is to overlap the cloned DNAs through the gene candidate region. Once a contig has 
been set up, genes are searched among those cloned DNAs by different methods. One 
common strategy is based on partial or complete sequence information. Additionally, 
evolutionarily conserved homology to a relevant gene in a model organism can be used for 
selecting a candidate gene. Since the first success of positional cloning was for the gene 
mutated in chronic granulomatous disease, many important disorders such as Duchenne 
muscular dystrophy, cystic fibrosis, Huntington disease, colorectal cancer, breast cancer, etc 
have been isolated by positional cloning73. Now progress in Human Genome Project is 
accelerating the identification of disease genes. 
  
The SPG4 locus was assigned to 2p by linkage analysis in 1994 (Hazan et al.34). Haplotype 
and linkage analysis in one Dutch and five French pedigrees delineated SPG4 within a 4 cM 
interval flanked by loci D2S400 and D2S367. Since then, many ADHSP families were           
described in whom the disease gene was assigned to 2p2,35.  
 
Nielsen et al.51 searched for CAG trinucleotides expansions in SPG4 due to the observation of 
posssible anticipation in ADHSP34,74. Anticipation refers to earlier disease onset and greater 
severity of the disorder in consecutive generations of a family. The molecular basis of 
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anticipation was discovered in trinucleotide repeat expansion disorders. The unstable 
trinucleotide repeat expansions cause many human hereditary diseases. Such unstable repeat 
expansions can be divided into two different classes.73 
 
The first class contains very large expansions of repeats outside coding regions of the gene. A 
(CGG)n repeat expansion occurs in the 5’UTR of Fragile-X site A (FRAXA)75. A (CCG)n 
repeat expansion is found in the promoter of Fragile-X site E (FRAXE)76. In Friedreich ataxia 
(FA)77, a (GAA)n expansion is found in intron 1. In myotonic dystrophy (DM)78, a (CTG)n 
expansion is found in the 3’UTR. 
 
The second class contains modest expansions of CAG repeats within coding regions. (CAG)n 
trinucleotide expansion is the most notable example. (CAG)n repeat expansions are associated 
with Huntington disease (HD)79, spinal and bulbar muscular atrophy (SBMA; Kennedy 
disease)80, spinocerebellar ataxia type 1 (SCA1)81, spinocerebellar ataxia type 2 (SCA2)82 , 
Machado-Joseph disease (MJD;SCA3)83, spinocerebellar ataxia type 6 (SCA6)84, 
spinocerebellar ataxia type 7 (SCA7)85, and dentatorubral-pallidoluysian atrophy (DRPLA)86. 
All these CAG repeats are located in the coding region of respective genes and encode 
polyglutamine tracts within the gene product.  When the length of polyglutamine tracts 
exceeds the threshold, the protein aggregates and forms inclusion bodies that appear to cause 
apoptosis of neuronal cell. The unstable CAG repeat numbers within coding regions are 
summarized in Table 15. 
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Table 15. Expansions of CAG repeats within coding regions of various diseases 
_____________________________________________________________________ 
Disease                               Wild-type repeat number              Expanded repeat number 
HD      6-35    36- >100 
SBMA     9-35    38-62 
SCA1     6-38    39-83 
SCA2     14-31    32-77 
SCA3     12-39    62-86 
SCA6     4-17    21-30 
SCA7     7-35    37-200 
DRPLA    3-35    49-88 
_______________________________________________________________________ 
 
 
Nielsen et al.51 reported that CAG repeat expansion had been detected in 20 individuals 
affected with SPG4. They used the repeat expansion detection (RED) method, which does not 
indicate the location of the CAG repeats. This method, which was based on oligonucleotide 
amplification and ligation, was developed by Shalling et al.52 in order to assay the unstable 
repeat expansions in human genome. The strategy for RED is to use a long repeat in genomic 
DNA as a template for the annealing of multiple complementary oligonucleotide molecules. In 
this method, oligomers of a given trinucleotide repeat are ligated together by thermostable 
ligase when they anneal in adjacent positions, forming a mixed population of longer single 
stranded molecules. Detection of the single stranded molecules is facilitated by a cycling 
procedure and achieved by separation on a denaturing polyacrylamide gel and subsequent 
electrotransfer and hybridization.  
 
One year later than Nielsen et al detected the CAG repeats in SPG4, Benson et al.87 found that  
in most cases of their ADHSP families  the repeat expansion detected by RED is due to non-
pathogenic CAG expansions in SEF2-1 locus88 on 18q21.1, which encodes a basic helix-loop-
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helix DNA binding protein involved in transcriptional  regulation or ERDA1 (expanded repeat 
domain, CAG/CTG 1) locus89 on 17q21.3. The CAG expansions were also detected in a 
subset of affected and at-risk at loci other than SEF2-1 and ERDA1 loci.  
 
Due to the possible occurrence of anticipation in ADHSP, the CAG/CTG repeats fragments 
within the SPG4 critical region were screened in this dissertation. A total of  6 sets of 
CAG/CTG repeat fragments were isolated from cosmid libraries. Of the CAG/CTG repeat 
fragments, clone D1 contains a disrupted single CAG unit; clone A8 contains (CAG)3, clones 
D5 and D6 contain (CAG)2; and clones D4 and E11 contain (CTG)6. Because the repeat 
number of trinucleotides involved in diseases is usually more than 3, two primer pairs which 
flanked the two sequences with 6 repeat units were generated in order to test for trinucleotide 
repeat expansions. The results do not support that CAG repeat expansion is involved in SPG4 
and were later confirmed by Del-Favero et al90. and Hazan et al.37. Del-Favero et al. searched 
for CAG/CTG fragments on the basis of  homologous recombination in SPG4 and their results 
suggested no CAG expansion in SPG4. Similar to our studies (Lau et al.50 1998), Hazan et al. 
later searched for CAG repeat fragments by building a BAC contig of SPG4 critical region. 
The authors also did not find any evidence of CAG repeat expansions as the cause of SPG4.  
 
As described previously, BACs/PACs clone contig is prerequisite for a sequence-ready map. 
While this contig was being constructed as initiated by us, Hazan et al.36 discovered the SPG4 
gene using the same strategy of positional cloning. The authors sequenced 2p21-24 as 
participants in Human Genome Project. They first constructed a BAC-based sequence ready 
map of the narrowed SPG4 interval which was estimated to be approximately 1.5Mb. The 
contig comprised 37 BAC clones and 32 STSs including 14 ESTs. The BAC clones were 
isolated from two human genomic libraries CITB_978_SKB and RPCI-11 using various 
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STSs. Sequencing of 12 of the 37 BAC-inserts and subsequent comparison to nucleic acid and 
protein databases, revealed  a total of 14 putative transcription units in this interval. Among 
the 14 genes detected by sequence analysis, 6 had been previously identified as ESTs and 3 
were known genes; xanthine dehydrogenase54, steroid 5α-reductase91 and TGF-β1 binding 
protein.55 The remaining 5 genes were only detected DNA sequence applying gene fishing 
programs to the available. One of these five genes showed homology in the 3’ coding region  
to genes that encode proteins of the AAA family. This gene was called SPAST after mutations 
were detected in SPG4 patients. 
  
 
5.2 Mutation Detection of SPAST 
Many mutations have been detected in SPAST in ADHSP patients92,93,94,95,96,97. These 
mutations are listed in Table 16 and include 72% base substitutions, 24% deletions, and 4% 
insertions. Of the  base substitutions, 60% occurred in the  coding region of SPAST while the 
other 40% were found at splicing sites. All insertions occurred in coding regions. Most of the 
deletions (92%) occurred in the coding region as well, yet 8% were intronic. In total, 70% of 
the mutations were found in exons and 30% in introns. These mutations were scattered 
throughout the SPAST gene. However, exon 5 was the most frequently mutated exon (7/42). 
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Table 16.  Mutations of SPAST found in SPG4 patients  
__________________________________________________________________________________
Mutation class Location Mutation Amino acid change Consequence 
__________________________________________________________________________________
Base substitution Exon 1 256C>T S44L Missense94 
 Exon 1 334G>T E112Stop Missense96 
 Exon3 702C>T Q193Stop Nonsense92 
 Exon 5 859C>G S245Stop Nonsense94 
 Exon5 873A>T K229Stop Nonsense92 
 Exon5 907C>A S261Stop Nonsense92 
 Exon5 932C>G Y269Stop Nonsense92 
 Exon7 1210C>G S362C Missense92 
 Exon8 1233G>A G370R Missense92 
 Exon8 1267T>G F381C Missense92 
 Exon8 1283T>G N386K Missense92 
 Exon8 1288A>G K388R Missense92 
 Exon9 1195C>T R399Stop Nonsense96 
 Exon9 1211C>T S404F Missense96 
 Exon10 1395A>G R424G Missense94 
 Exon10 1401C>G L426V Missense92 
 Exon10 1416C>T R431Stop Nonsense92 
 Exon11 1447A>G D441G Missense93 
 Exon11 1468G>A C448Y Missense92 
 Exon11 1504G>T R460L Missense92 
 Exon13 1620C>T R499C Missense92 
 Exon14 1583G>A G527D Missense96 
 Exon15 1788G>A D555N Missense92 
 Exon15 1792C>T A556V Missense92 
 Exon15 1809C>T R562Stop Nonsense92 
 Exon17 1875G>C D584H Missense94 
 Intron4 808-2a>g  --- Missplicing92 
 Intron6 1129+2t>g  --- Missplicing92 
 Intron7 1223+1g>t  --- Missplicing92 
 Intron8 1298+1g>a  --- Missplicing94 
 Intron8 1299+1g>a  --- Missplicing92 
 Intron11 1538+3a>c  --- Missplicing94 
 Intron11 1538+5g>a PTC+6 aa Exon11 skipping 
+frameshift92 
 Intron12 1618+2t>a  --- Missplicing94 
 Intron13 1661+1g>t  --- Missplicing94 
 Intron13 1661+2t>c  --- Missplicing92 
 Intron13 1662-2a>t  --- Missplicing92 
 Intron15 1812+1g>a  --- Missplicing92 
 Intron15 1812+2t>g  --- Missplicing94 
 Intron15 1813-2a>g  --- Missplicing92 
 Intron16 1853+1g>t Exon16 skipping Missplicing93,95 
 Intron16 1853+1g>a  --- Missplicing92 
 Intron16 1853+2t>c  --- Missplicing94 
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Deletion Exon1 411delG PTC+64aa Frameshift94 
 Exon5 852-862del PTC+18aa Frameshift92 
 Exon5 906delT PTC+17aa Frameshift92 
 Exon7 1206-1209del PTC+1aa Frameshift97 
 Exon9 1299delG PTC+3aa Frameshift92 
 Exon9 1340-1344del PTC+35aa Frameshift93 
 Exon10 1406delT PTC+10aa Frameshift94 
 Exon11 1520delT PTC+1aa Frameshift92 
 Exon12 1574-1575del PTC+2aa Frameshift92 
 Exon12 1617-1678del Exon11-12 and Missplicing93 
  Exon11-13 skipping 
 Exon13 1634-1655del PTC+18aa Frameshift92 
 Exon14 1685-1688del PTC+7aa Frameshift92 
 Intron11 1538+3-1538+6del  --- Missplicing94 
   
Insertion Exon2 578-579insA PTC+2aa Frameshift92 
 Exon4 709-710insA PTC+21aa Frameshift96 
 Exon5 882-883insA PTC+12aa Frameshift92 
 Exon14 1684-1685insTT PTC+9aa Frameshift92 
__________________________________________________________________________________
Note: Nucleotide numbers refer to the SPAST cDNA sequence. Upper case letters represent bases in 
exons, lower case letter in introns. Amino acid (aa) numbers refer to the spastin petide sequence. 
PTC+n,premature termination codon at n amino acids downstream from the location of mutation. 
 
There are several methods for mutation screenings based on various application as follows. 
(1) Heteroduplex/SSCP98analysis  has been the most frequently used method for mutation 
detection. Many modified methods  are based on the formation of heteroduplexes which 
have abnormal mobility on nondenaturing  polyacrylamide gels and abnormal denaturing 
profiles . SSCP gel electrophoresis is a simple method for distinguishing fragments shorter 
than 300 bp, which can have  insertion, deletion and most but not all single-base 
substitutions. Denaturing gradient gel electrophoresis99 (DGGE) and denaturing high 
performance liquid chromatography (dHPLC) can separate heteroduplexes based on the 
mobility of the denatured fragments. DGGE requires special primers with a 5’ poly(GC) 
extension (a GC clamp). If optimized, these methods have very high sensitivity. The use of 
two dimensional DGGE gels can also increase the sensitivity for mutation detection.  
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(2) Chemical cleavage of mismatch (CCM) is a sensitive method for  mutation detection 
which is used to  analyze large fragments (over 1 kb) and the location of mismatch can be 
detected by the size of the fragments. The disadvantage is however the use of very toxic 
chemicals , such as osmium tetraoxide. An alternative is to use T4 phage resolvase or 
endonuclease VII  for cutting heteroduplexes. This method however is not easily 
optimized.100 
 
(3) The protein truncation test (PTT) is a specific test for frameshifts, splice site  or nonsense 
mutations that truncate a protein product101. For the diseases, such as Duchenne muscular 
dystrophy, adenomatous polyposs coli or  BRCA1-related breast cancer in which missense 
mutation is infrequent, PTT is  useful because it ignores silent or missense mutation, and 
also reveals  the approximate location of the mutation. 
 
(4) High-density oligonucleotide arrays which are based on oligonucleotide hybridization can 
be used for a high throughput mutation scanning 102. This technique is applied to the 
mutation scanning of the known genes. Two basic designs are as follows: Hybridization 
chips contain oligonucleotides matching all wild-type and single nucleotide substitution 
sequences in a gene. Test DNA is PCR-amplified, fluorescently labeled and hybridized to 
the array. Generally, homozygous base substitutions are easily detected, but heterozygous 
substitution detection can be difficult and detection of insertion mutations is almost 
impossible. Minisequencing chips use arrayed oligonucleotide primers with free 3’-OH 
groups. Unlabeled PCR-amplified test DNA is hybridized to the array, and DNA 
polymerase plus four differently labeled dideoxynucleotides are added. The test DNA acts 
as  template for addition of a single labeled dideoxynucleotide to each array primer. The 
additions will occur only if the 3’ end of the primer exactly matches the template. The array 
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can be made with primers specific not only for the wild-type sequence but also for all 
possible  mutations. 
 
(5) RT-PCR analysis: In addition to testing genomic DNA, mutation detection by RT-PCR  
allows study of aberrant splicing and also base changes in exons. However, not all genes 
are expressed in readily accessible tissues and RNA is much less stable; in particular 
mRNA. Transcripts which exist in cells that  are  not expected to express such mRNA  are 
so-called ectopic or illegitimate transcprits103. Caution should be taken in interpretation of 
aberrant splicing product of ectopic transcripts , because the structure of ectopic transcripts 
are not always faithful. In addition, many mutations result in unstable mRNA  so that only 
the wild-type transcript of a  heterozygous patient can be detected by RT-PCR. An aberrant 
RT-PCR product lacking exon 8 in SPAST from a patient  in that large SPG4-linked family 
was detected. In our lab-control samples, the same splicing artifact was observed after 
blood samples were placed for 10 hr at room temperature.  
 
As shown in this dissertation, a single patient of a small pedigree was detected a mutation in 
SPAST but the mutation of the large SPG4-linked family was not found. The same 
phenomenon was also reported in other  SPAST studies104. The reason may be that the 
mutations in these SPG4-linked family are gross deletions or another atypical intronic 
mutation. Sequencing is the direct and also still the most reliable method when both strands 
are sequenced to detect mutations. However, it is expensive and time-consuming to scan many 
exons of a gene and  exclude artifacts. 
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Although sequence changes can be detected by many techniques as described above, not every 
sequence variant of an affected person is necessarily pathogenic. There are some criteria for 
deciding whether a DNA sequence change is pathogenic73. These are described as follows: 
 
(1)Deletions of an entire gene, as well as nonsense and frameshift mutations probably abolish 
    the gene function. 
(2) Mutations in  the  conserved GT..AG  nucleotides  flanking  most  introns  affect splicing, 
and usually alter the function of the gene. 
(3)A missense mutation is likely  to be pathogenic if it alters the domain of protein proved  
     to be functionally important. 
(4) Change of amino acids in the evolutionarily conserved domain across species or between  
 members of a gene family  is possible to be pathogenic. 
(5) Amino acid substitutions where a polar amino acid is replaced by a nonpolar amino acid;  
or where an acidic amino acid  is replaced by a basic amino acid  are  likely to alter  gene 
function  
(6) A sequence change in a disease gene of a de novo affected patient that is not in the  
unaffected parents is likely to  be pathogenic. 
 
5.3 Hypothesis of Spastin Function 
On the basis of sequence homology, several hypotheses of spastin function have been           
proposed36. The high homology with the 26S proteasome subunit  as well as the presence of 
two leucine-zipper domains and a coiled-coil dimerization  suggest that spastin participates in 
protein complexes. Proteasomes are large multi-catalytic protease complexes involved in      
major proteolytic pathways in both the cytoplasm and the nucleus105. They function in cellular 
processes such as cell differentiation, adaptation to environmental stress, cell cycle control 
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and transcription regulation. There is also striking homology between spastin and Sap1p, a 
yeast nuclear AAA protein  thought to interact with the chromatin protein Sin1p106. The 
change in yeast mating type occurs via a cassette mechanism in which one of the silent copies 
replaces the active gene at the MAT (mating type) locus changing the mating type. This 
process is controlled by an endonuclease which is the product of the HO (homothallism) gene 
and which makes a double-stranded cut at the MAT locus initiating switching. Sin 1p is one 
of SIN loci which encode transcription factors that repress HO gene expression. Nuclear AAA 
proteins exhibiting homology with 26S proteasome subunits have been suggested to play an 
indirect role in gene expression by mechanisms that include proteolytic activation or 
degradation of transcription factors.107,108 
 
An other proposed function of spastin is that of a chaperone in corticospinal tract preservation. 
This idea comes from the comparison with the Paraplegin25 gene at chromosome 16q24.3. 
Mutations in paraplegin cause autosomal recessive SPG7, resulting from typical 
mitochondrial oxidative phosphorylation (OXPHOS) impairments and  result in both pure and 
complicated forms of AR-HSP. The Paraplegin gene encodes a protein, paraplegin, that is 
highly homologous to the yeast mitochondrial ATPases, AFG3, RCA1, and YME1. These 
ATPases have both proteolytic and chaperone-like activities at the inner mitochondrial 
membrane. Another autosomal dominant neurondegenerative disease, early onset torsion 
dystonia, is caused by a mutation in the DYT1 gene which encodes torsinA. TorsinA is also a 
member of the AAA family and functions as a chaperone protein in the transport of 
dopamine-containing membranous vesicles.109 Thus the functions of paraplegin and torsinA 
indicate that spastin may play a chaperone-like role. 
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The SPAST gene is expressed ubiquitously in brain, heart, liver, kidney, pancreas, skeletal 
muscle, and lymphocytes36. However, the primary pathology is the degeneration of the 
neurons. This indicates that mutations may have different effects in different cell types in 
which the gene is expressed and a tissue-specific vulnerability in SPG4 which results in the 
degeration of neurons. Selective vulnerability is a common phenomenon in many human 
neurondegenerative diseases110. For example, Huntigton’s disease results in cell death in the 
caudate and causes in abnormal movement. Parkinson’s disease destroys cells in the 
substantia nigra and causes rigidity and tremor of movement. Amyotrophic lateral sclerosis 
destroys the lower motor and pyramidal neurons and results in weakness and spasticity. 
However, the selective vulnerability is not absolutely sustained during the process of disease. 
For example, patients with Huntington’s disease, Parkinson’s disease, and amyotrophic lateral 
sclerosis can develop dementia, implying cortical pathology involved in late stage of the 
disease. Patients with Alzheimer’s disease frequently develop parkinsomism. The selective 
vulnerability might be due to the variability of the gene expression or interaction with tissue-
specific polypeptides, however, the mechanism is still unclear. 
Heinzlef et al.111 mapped a complicated familial spastic paraplegia to locus SPG4 on 
chromosome 2p, although SPG4 locus is frequently associated with pure HSP. Recently, 
another three reports of the pedgrees from Ireland, France, and England have described the 
association of  SPG4-linked autosomal dominant pure HSP with dementia , epilepsy, or 
both112,113,114, although SPG4 occurs frequently in a pure form. In addition, a study on five 
Danish SPG4-linked families revealed  bowel, bladder and sexual dysfunction suggesting that 
autonomic system was involved in SPG4-linked ADHSP115. Pure HSP is thought as a disease 
of the CNS long tracts. The reason why an alteration in Spastin leads to specific axonal 
degeneration and more complicated pathology remains to be explored116.  
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5.4 Hypothesis of mutation effect in SPAST 
Hazan et al.36 and Bürger et al.93 suggested that SPG4 is caused by a loss of function due to 
mutations. This implied that a threshold dosage of spastin was critical for neuronal 
preservation and SPG4 exerted the dominant effect by haploinsufficiency. The phenotype of 
point mutations in a gene is likely  the same pathological change as deletions which imply the 
loss of function. However, many different changes in a gene can lead to loss of function, for 
examples, the structural abolishment in a gene (including deletion, insertion, translocation, 
inversion), disturbance in the promoter region, destablization of the mRNA, and errors in 
splicing and post-transcriptional processing. Haploinsufficiency refers to the case where a 
50% reduction in the level of gene function causes an abnormal phenotype. This posssibly 
explains why SPG4 has incomplete penetrance and wide variation of phenotype between 
affected individuals, even within families. Recently, a nonpenetrance at the SPG4 locus was 
reported where the carrier was 26 years older than the maximal age of onset for her family114. 
This suggests that gene modifiers are involved in the process of the neuronal degeneration 
resulting from mutation of SPAST.  
 
Human genes which show haploinsufficiency effect that means two alleles are needed for a 
normal phenotype fall into the three categories: 117 
(1) Transcriptional regulators: PAX3  (Waardenburg syndrome), PAX6 (aniridia), GLI3 (Greig 
cephalopolysyndactyly), ZNF141 (Wolf-Hirschhorn syndrome), TUPLE-1 (CATCH22 
syndromes), and WT1 (Wilms’s tumor). 
(2) Structural molecules: elastin (supravalvular aortic stenosis), ankyrin (spherocytosis type 
II), and type 1 collagen (osteogenesis imperfecta). The abnormal heterozygous phenotypes 
result in the imbalance with a matched component protein. 
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(3) Receptors and signal transduction molecules: RET (Hirschprung disease) and LIS-1 
(Miller-Dieker lissencephaly) result in the false  stoichiometry of intermolecular complexes 
in the abnormal heterozygote. 
 
Except haploinsufficiency described above, dominant mutations can exert their effects in 
various ways. Some mechanisms of dominant mutations which present gain of function are 
discussed below118. 
 
(1) Increased gene dosage: Trisomy in humans is usually associated with phenotypic 
abnormality which may be relevant when the increase in dosage at the mRNA and protein 
level  exceeds the expected factor of 1.5. Studies of Down syndrome119 with translocations 
show the critical region is in chromosome 21q22.2. At least two candidate genes for mental  
retardation have been identified from this region: DYRK, a gene whose drosophila and 
mouse homologues (minibrain) produces dosage sensitive learning defects, and DSCAM, a 
brain-specific cell adhesion molecule120. Gene amplification in somatic cells to much 
higher copy numbers frequently occurs in cancer. For example, a dominant phenotype is 
caused by the amplification of the MDM2 gene in sarcomas. MDM2 protein binds and 
inactivates the tumor suppresser gene P53, leading to escape from normal p53 regulated 
cellular growth control.121 
 
(2) Ectopic or temporally altered mRNA expression:  The exquisite controls of mRNA          
expression that dictate the normal cellular distribution, temporal restriction, and absolute 
levels of mRNA are disturbed in some disorders. The disease phenotype may reflect a 
combination of alterations in the temporal specificity, tissue distribution, and absolute level 
of mRNA expression. In this case, the  primary abnormality usually lies at the level of     
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transcription, but sometimes mRNA processing may be affected. chromosomal              
translocations resulting from errors in recombinase-mediated gene rearrangement in         
lymphocytes activate expression of transcription factors like MAC, causing B and T cell 
neoplasms122,123. Promoter mutations in the Caenorhabditis sex determining gene, her-1,       
increase expression levels and result in  partial transformation of XX worms into 
phenotypic males124. Increased ectopic expression of a chimerical  mRNA encoding a 
normal protein causes the lethal yellow mutant at the mouse agouti locus125. A point 
mutation of the γ globin promoter, which alters binding of the erythroid transcriptional 
factor GATA-1, results in  hereditary persistence of fetal haemoglobin (HPFH). This 
mutation blocks the normal switch from expression of γ to δ and β globin that occurs 
around the time of birth.126 
 
(3) Increased or constitutive protein activity: At the protein level, increased activity may be 
caused by increased half life or by loss of normal inhibitory regulation. PEST sequences 
which are rich in proline, glutamic acid, serine, and threonine can  act as recognition       
signals for proteolytic degradation and loss of these sequences by C-terminal truncation 
stabilizes the protein127. The glp-1 gene of C elegans is required for induction of germline 
proliferation and embryogenesis. The glp-1 point mutation is particularly instructive, as it 
causes both semidominant (multivulva) and recessive (sterility/embryonic lethality)        
phenotypes which result from the destabilization of the mutant mRNA128. 
 
(4) Dominant negative mutations: In the heterozygous state, these mutants antagonise the                
activity of the remaining wild type allele. The mutant polypeptide loses not only its own     
function but also interferes with the product of the normal allele in a heterozygote. 
Dominant negative effects are very important in neoplasia. The tumor suppresser  p53 
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oligomerizes in vitro and can adopt two conformations, one active and the other inactive; 
wild type protein is normally in the active state. Cotranslation with certain missense 
mutants results in mixed  oligomers that adopt the inactive conformation. Although p53 is 
conventionally considered as a recessive tumor suppresser gene, some mutants can 
deregulate p53 function in a dominant negative pattern.129,130  
In addition, the disruptive interaction in toxic protein131, altered substrate specificity in mutant 
protein132, recessive antioncogene in retinoblastoma133, and parental genomic imprinting134 
provide a variety of examples of genetic dominance. 
 
5.5 Prospective View: 
The  isolation of  the SPAST gene and the establishment of  mutation spectrum have led the 
molecular diagnosis of SPG4 available. However, the functional study of SPAST, such as with 
transgenic models, is expected to illustrate the genetic and molecular pathology of SPG4. 
There are several fundamental  questions that need to be explored. 
(1) How is the mutant mRNA expressed in different  cell types? 
(2) How does the tissue specific vulnerability occur in SPG4? 
(3) Is there a SPAST modifier gene involved in the gene expression? 
(4) Spastin should be studied as well as to establish  rapid detection methods like ELISA or 
       RIA . 
In this dissertation, the mutation of this large SPG4-linked family could not be detected 
because of methodological limitation. However, a gross deletion or other intronic mutations 
should be considered. In future, new techniques such as nucleic acid chips and microarrays are 
expected to make a more rapid screening and mutation detection possible. Finally, it would be 
interesting to trap some genes  from the BAC and PAC contig  in which SPAST is located. 
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6 Conclusion 
 
Pure hereditary spastic paraplegias (pHSP) are relatively mild neurodegenerative  disorders of 
the spinal cord. The predominant clinical sign is a slowly progressive gait anomaly due to 
spasticity of the legs. Age of onset is usually during adulthood, but varies greatly both within 
and between families. Autosomal dominant hereditary spastic paraplegia (ADHSP) are the 
major forms of pHSP and are genetically heterogeneous. The  disease loci of pure ADHSP 
have been assigned to chromosomes 2 (SPG4 in 2p 21-24, SPG13 in 2q24-34), 8 (SPG8 in 
8q23-24), 12 (SPG10 in 12p13), 14 (SPG3 in 14q11.2-q24.3), 15 (SPG6 in 15q11.1), and              
19 (SPG12 in 19q13). To date, the SPG4 gene SPAST has been identified. The purpose of this 
dissertation is to (1) determine the disease locus of a large family with pure ADHSP, (2) 
construct the physical map of the candidate region as the first step to identify the disease gene, 
(3) investigate whether CAG repeat expansions were involved in the mechanism of disease, 
and (4) screen the mutation of patients with the SPAST gene. The results are summarized 
below.  
 
(1) The large family with pure ADHSP was analyzed  by linkage test  and a significant 
linkage of the disease loci to SPG4  with lod scores = 3.63 and 3.39  at loci D2S367 and 
D2S352, respectively was found.  
 
(2) A yeast artificial chromosomes (YAC) contig which comprised 10 additional YACs and 
13 expressed sequence tags (ESTs) on the basis of the previously published YAC contig of 
SPG4 critical region was constructed.  
 
(3) A total of  six CAG/CTG containing fragments were obtained from cosmid libraries 
within the SPG4 candidate region between loci D2S367 and D2S400. Of the six CAG 
containing sequences, a highly polymorphic STRP (D2S3008) was serendipitously 
identified. It  is composed of (GAAA)n(AAGG)n. A total of 28 alleles were identified in 
50 Caucasian DNA samples. The marker has a heterozygosity of 0.81 and a PIC value of 
0.78.  Loci D2S352 and D2S2283 flank D2S3008 distally and D2S2351 flank it proximally. 
A 254 bp allele at locus D2S3008 was segregated in the affected individuals of the SPG4-
linked family.  
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(4) Based on the sequences of the remaining five CAG positive clones, five new STSs were 
generated and  their  dbSTS_ID are 98663, 98664, 98809, 98810, 98811, respectively. Two 
of the six fragments showed the maximum of repeat units was (CTG)6. However, no 
CAG/CTG repeat expanded alleles were detected in the affected individuals of the SPG4-
linked family.  
 
(5) A contig which comprised 33 bacteriophage P1-derived artificial chromosomes (PACs) 
and 15 bacterial artificial chromosomes (BACs) was established in the SPG4 candidate 
region. The sizes of PACs and BACs were determined by pulse field gel electrophoresis 
and the average size of PACs and BACs was 120 kb and 127 kb, respectively. In addition, 
a total of 41 STSs comprising 26 ESTs were integrated into this contig. Of the 26 ESTs, 
SHGC12567 was found to be part of human xanthine dehydrogenase, N52847 was 
identical with  human latent transforming growth factor beta binding protein 1 (LTBP1), 
and  stSG 4150 and stSG 1707 were a part of human EH domain containing protein 3 
(EHD3). The remaining ESTs had no striking homology with the known genes. 
 
(6) A novel mutation 1206-1209delCCTT in the exon 7 of SPAST was identified (Human 
Gene Mutation Data Accession Number: H971836) in one patient. In addition, one 
polymorphism 1298+17A>C in the intron 8 of SPAST was detected and the same 
polymorphism was found in one of 100 unrelated controls. There was no mutation found in 
the SPG4-linked family when all 17 exons, 5’UTR, 3’UTR, and introns 6,10,11 were 
sequenced. The mechanism of  mutation in the SPG4-linked family has to be further 
investigated for gross deletion or atypical intronic mutation. 
 
 
 
 
 
 
 
 
 
 
 
________________________________________Conclusion_____________________________________ 
 
97
 
Zusammenfassung 
 
Reine hereditäre spastische Paraplegie (pHSP) bezeichnet eine Gruppe von relativ gutartigen 
neurodegenerativen Erkrankungen des Rückenmarks. Das hervorstechende klinische 
Symptom ist eine langsam fortschreitende Gang-Anomalität, die durch eine Spastik der Beine 
begründet ist. Autosomal dominante hereditäre spastische Paraplegien (ADHSP) sind die 
Hauptformen von pHSP und sind genetisch heterogen. Als Genorte für die reine ADHSP 
wurden die Chromosomen 2 (SPG4 auf 2p 21-24, SPG13 auf 2q24-34), 8 (SPG8 auf 8q23-
24), 12 (SPG10 auf 12p13), 14 (SPG3 auf 14q11.2-q24.3), 15 (SPG6 auf 15q11.1), und 19 
(SPG12 auf 19q13) identifiziert. Bis zum heutigen Tag wurde allein das in SPG4-Patienten 
mutierte SPAST-Gen kloniert und analysiert. 
Die Ziele dieser Dissertation sind: (1) Bestimmung des Krankheitslocus einer großen Familie 
mit reiner ADHSP; (2) Erstellung einer physikalischen Karte der Kandidaten-Gen-Region, um 
Kandidaten-Gene untersuchen zu können; (3) Untersuchung, ob CAG-Repeat-Expansionen 
für die Krankheitsentwicklung verantwortlich sind und (4) Suche nach neuen Mutationen im 
SPAST-Gen. Die Ergebnisse sind hier kurz zusammengefasst: 
 
(1) Bei einer großen Familie mit reiner ADHSP wurde eine Linkage-Analyse durchgeführt 
und eine signifikante Assoziation der SPG4 Krankheitsloci mit lod score Werten von 3.63 am 
Locus D2S367 und 3.39 am Locus D2S352 erhalten. 
 
(2) Eine Yeast Artificial Chromosome (YAC) Contig, die 10 zusätzliche YAC's und 13 EST's 
beinhaltet, wurde auf der Basis der zuvor veröffentlichten YAC Contig der SPG4-kritischen 
Region erstellt. 
 
(3) Sechs Fragmente mit CAG/CTG Sequenzen wurden aus einer Cosmid-Genbank aus der 
SPG4 Kandidatengen-Region zwischen den Loci D2S367 und D2S400 isoliert. Bei der 
Analyse dieser sechs CAG-Sequenzen beinhaltenden Fragmente wurde ein hoch polymorpher 
STRP (D253008) zufällig identifiziert. Dieser STRP hat die Struktur (GAAA)n(AAGG)n und 
es konnten 28 Allele in 50 kaukasischen DNA-Proben identifiziert werden. Dieser Marker hat 
eine Heterozygosität von 0.81 und einen PIC Wert von 0.78.  
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Die Loci D2S352 und D2S2283 flankieren den Marker D2S3008 distal und D2S2351 
flankiert ihn proximal. Ein 254 bp Allel am Locus D2S3008 segregiert mit den betroffenen 
Individuen aus der SPG4 zugeordneten Familie. 
 
(4) Die verbleibenden fünf CAG-positiven Klone konnten genutzt werden, um fünf neue STSs 
(98663, 98664, 98809, 98810 und 98811) zu generieren. Zwei der sechs Fragmente 
beinhalteten sechs CTG-Repeat-Einheiten. In den Patienten der SPG4 assoziierten Familie 
konnte jedoch keine Expansion eines CAG/CTG Repeat-Allels nachgewiesen werden. 
 
5) Über die SPG4 Kandidatenregion wurde ein Contig gelegt das aus 33 P1-Bakteriophagen 
Artifiziellen Chromosomen (PAC's) und 15 Bakteriellen Artifiziellen Chromosomen (BAC's) 
besteht. Die Längen der BAC's und PAC's wurden über Pulsfeld Gelelektrophorese bestimmt, 
die Durchschnittsgröße der PAC's belief sich auf 120kB, die der BAC's auf 127 kB. 
Zusätzlich wurde eine Summe von 41 STS's, die 26 EST's beinhalteten, in diesem Contig 
lokalisiert. Einige der 26 EST's wurden Genen zugeordnet: SHGC12567 wurde als Teil der 
humanen Xanthin Dehydrogenase erkannt; N52847 war identisch mit dem Human Latent 
Transforming Growth Factor Beta Binding Protein 1 (LTBP1); und sowohl stSG 4150 als 
auch stSG 1707 wurden als Teile des Humanen EH Domain Containing Protein 3 (EHD3) 
erkannt. Die weiteren EST's zeigten keine deutlichen Homologien zu bekannten Genen. 
 
(6) In einem Patienten wurde im Exon 7 von SPAST eine neue Mutation 1206-1209(CCTT 
identifiziert (Human Gene Mutation Data Accession Number: H971836). Zusätzlich wurde in 
Intron 8 ein Polymorphismus 1298+17A>C gefunden, der aber auch in einer der 100 nicht 
verwandten Kontrollpersonen vorkam. In der Familie mit SPG4-Link konnte in allen 17 
Exonen, sowie in 5'UTR, 3'UTR und Introns 6, 10, 11 von SPAST über DNA-Sequenzierung 
keine Mutation gefunden werden. Die Art der Mutation in der Familie mit SPG4-Link bleibt 
also noch zu bestimmen. Es könnte sich um eine große Deletion oder um eine atypische 
intronische Mutation handeln. 
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